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PATHOLOGY 
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JOHN STEWART LOWE 
 
Dissertation under the direction of Professor Peter J. Mohler 
The focus of this project is determining if an ankyrin-G-based pathway 
controls the membrane expression of the voltage-gated sodium channel 1.5 
(Nav1.5) in cardiomyocytes.  Disruption of the normal localization of Nav1.5 can 
lead to a fatal cardiac arrhythmia termed Brugada Syndrome and has been 
linked to myopathic cardiac disease.   
This project defines that an ankyrin-G-based pathway controls the  
expression, localization, and function of Nav1.5 at the cardiomyocyte plasma 
membrane.  These studies were accomplished by developing a primary cell 
culture system where ankyrin-G could be reduced and selectively restored to 
define if Nav1.5 targeting was truly dependent on a direct interaction with an 
ankyrin-G-based mechanism.  Moreover, these studies have identified the 
residues on ankyrin-G necessary for the interaction of Nav1.5 and ankyrin-G.  
Together, these findings provide critical clues in understanding the molecular 
mechanism of Nav1.5 targeting in the cardiomyocyte and have developed 
exciting new tools for studying the targeting pathway. 
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CHAPTER I 
 
THE ELECTRICAL BASIS OF CARDIAC FUNCTION 
 
 The human heart beats approximately two billion times during the course 
of an average human lifetime (Dobson, 2003).  The precisely coordinated 
contraction and relaxation events of each heart beat are controlled by complex 
molecular mechanisms (Roden et al., 2002).  Disruption of the rhythmic activity of 
the heart (arrhythmia) may result in the drop of oxygenated blood to the brain 
and peripheral tissues (Rubart and Zipes, 2005).  In fact, half a million fatalities a 
year are associated with an arrhythmic event (Yu and Catterall, 2003).  
Therefore, understanding the mechanisms underlying potentially fatal cardiac 
arrhythmias is critical for the treatment and diagnosis of human disease.  
 Currents from ion channels and transporters combine to form the electrical 
signals that control cardiac rhythm.  These electrical signals are called action 
potentials.  Heart rhythm is controlled by the coordinated propagation of action 
potentials through specialized electrically-excitable cardiac cells and tissues 
(Ackerman and Clapham, 1997; Bers, 2001a; Roden et al., 2002).  Chapter 1 will 
introduce the mechanisms governing ion channel and transporter function for 
action potential development.  Additionally, Chapter 1 will discuss how ion 
channel dysfunction may result in human cardiovascular disease.  Finally, this 
chapter will provide special emphasis on the role of voltage-gated Na+ channels 
in cardiac function and disease.  
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Cardiac structure and action potentials 
 
 The mammalian heart has four chambers. Bilateral atria accept blood from 
peripheral (right atria) and pulmonary (left atria) tissues, whereas the bilateral 
ventricles pump blood out into the pulmonary (right) and peripheral (left) tissues 
(Figure 1A).  This highly coordinated pumping action of the heart supplies blood 
to all tissues.  Blood carries oxygen and nutrients to sustain the metabolic needs 
of all cells.  The coordinated pumping activity of the heart is controlled by the 
transmission of action potentials between specialized cardiac cell types.  
Action potentials spread through diverse cardiac cell types via tightly 
controlled electrical pathways (Bers, 2001; Roden et al., 2002).  Specifically, the 
heart contains a number of specialized electrically-excitable cell types including 
sinoatrial node myocytes, atrial myocytes, atrioventricular node myocytes,  His-
Purkinje fibers, and ventricular myocytes (Figure 1) (Schram et al., 2002).  Each 
heartbeat initiates in the sinoatrial node via an impulse fired from the rhythmic 
cycles of depolarization controlled by pacemaker currents (If) (Figure 1) (Schram 
et al., 2002).  The initial sinoatrial node stimulus is then transmitted to the atria.  
Atrial myocytes subsequently trigger action potentials that spread throughout the 
atria, which pause briefly in the atrioventricular node (Figure 1A) (Schram et al., 
2002).  During this pause, the atria load the ventricles with blood (Schram et al., 
2002).  The atrioventricular node then transmits an action potential through the 
His-Purkinje system and the ventricular myocardium, resulting in the coordinated 
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pumping of blood to the lungs and peripheral tissues (Figure 1A) (Schram et al., 
2002).  Action potential shape and velocity of propagation through sinoatrial and 
atrioventricular tissue is unique from other cardiac excitable tissues (Figure 1B) 
(Schram et al., 2002).   These unique electrical properties allow the coordinated 
depolarization and thus contraction of the entire myocardium.   
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Figure 1. 
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Figure 1. Basic heart structures and action potential components. A. The 
working myocardium is composed of bilateral atria and ventricles. The heartbeat 
is coordinated by the initiation of an electrical impulse (action potential) in the 
sinoatrial node, conduction through the atria to the atrioventricular node, and 
then conduction through the His-Purkinje system into the ventricles. B. Action 
potential morphology and velocity varies between the different cell types of the 
heart. This figure was adapted from Schram et al. Circulation Research 2002 
(Schram et al., 2002). 
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The ventricular action potential 
 
 Ventricular action potentials have five phases (Figure 2).  Phase 0 is 
controlled by the rapid activation/inactivation of the primary cardiac voltage-gated 
Na+ channel (Nav1.5) that drives the upstroke of the action potential (Figure 2) 
(Nerbonne and Kass, 2005; Schram et al., 2002).  Near the end of phase 0, a 
transient outward current (Ito) offsets the inward sodium current with a 
repolarizing current that results in the phase 1 “notch” (Figure 2) (Nerbonne and 
Kass, 2005; Schram et al., 2002).  Phase 2 correlates with the action potential 
plateau that is the result of a balance between inward (Ca2+) and outward (K+) 
currents (Nerbonne and Kass, 2005; Schram et al., 2002).  Phase 3 is a 
repolarizing phase controlled by the inactivation of ICa,L and the increased activity 
of IKs and IKr (delayed-rectifier K+ channels) (Schram et al., 2002).  IKs and IKr are 
voltage-gated K+ channel currents that are activated as the membrane voltage 
repolarizes after Phase 2.  Phase 4 marks the return to resting potential that is 
maintained by IK1 in ventricular tissue (Figure 2).   
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Human ventricular action potential 
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Figure 2.  Human ventricular action potential.  The five phases (arrows) of the 
cardiac action potential are controlled by the activation and inactivation of several 
ion channels and transporters.  The predominant currents that regulate each 
phase are listed (Figure 2). This figure was modified from Schram et al. 
Circulation Research 2002 (Schram et al., 2002). 
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 The primary ion channel currents that control the cardiac action potential 
are complemented by the activity of additional channels, pumps, and transporters 
including the Na+/Ca2+ exchanger, the Na+/K+ ATPase, the SR/ER Ca2+ ATPase 
(SERCA2a), the ryanodine receptor, the inositol 1,4,5, trisphosphate (IP3) 
receptor, and the plasma membrane Ca2+ ATPase (PMCA) (Lehnart et al., 2007; 
Priori and Napolitano, 2005).   
 
Human cardiac channel diseases (“Cardiac Channelopathies”) 
 
 Dysfunction in ion channels or transporters may result in human diseases 
termed “channelopathies”.  These cardiac “channelopathies” may be inherited, or 
acquired in response to drug interactions (Lees-Miller et al., 2000; Lehnart et al., 
2007; Mitcheson et al., 2000).  For example, a number of pharmaceutical 
compounds have been linked to increased risk of sudden cardiac death by 
altering the function of cardiac ion channels (Lehnart et al., 2007; Priori and 
Napolitano, 2005; Priori et al., 2001b).   
 Alternatively, human carriers of specific ion channel gene gain- or loss-of-
function variants may display cardiac channelopathies and risk for arrhythmia 
(Keating et al., 1991).  To date, variants in nine different genes including KCNQ1 
(LQT1; encodes KVLQT1, IKs potassium channel alpha-subunit) (Wang et al., 
1996), HERG (LQT2; encodes human ether-a-go-go-related gene, IKr potassium 
channel alpha-subunit) (Curran et al., 1995), SCN5A (LQT3; encodes Nav1.5,  
voltage-gated Na+ channel alpha-subunit) , KCNE1 (LQT5; encodes MinK, beta-
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subunit for IKs potassium) (Splawski et al., 2000), KCNE2 (LQT6; encodes MiRP, 
beta-subunit for IKr potassium channel) (Splawski et al., 2000), KCNJ2 (Anderson 
syndrome 1; encodes Kir2.1, potassium channel responsible for IK1 current) 
(Plaster et al., 2001), RyR2 (CPVT1; encodes ryanodine receptor calcium-release 
channel) (Priori et al., 2001b), and CACNA1C (Timothy Syndrome; encodes the 
cardiac voltage-gated Ca2+ channel, Cav1.2) have been implicated in human 
arrhythmia (Splawski et al., 2004).    
 
Human Na+ channelopathies 
 
 Nav channel variants that may alter biophysical function have been linked 
to Brugada syndrome, sick sinus syndrome, type 3 long QT syndrome, and atrial 
fibrillation (Balser, 2001).  Human SCN5A gain-of-function variants may result in 
prolongation of the cardiac action potential and type 3 long QT (LQT3) syndrome 
(Priori et al., 2002).  LQT3 syndrome is a potentially fatal cardiac arrhythmia, and 
the third most common form of long QT syndrome (Clancy et al., 2002; Moss et 
al., 1995).  LQT3 Nav1.5 variants may result in defects in channel inactivation 
gating that lead to a small persistent Na+ current and increases the potential for 
early after-depolarizations (triggers of ventricular fibrillation) (Roden et al., 2002; 
Schram et al., 2002).  The persistent LQT3 Na+ current offsets the outward 
currents of K+ channels in phase 2 of the cardiac action potential that leads to a 
prolonged QT interval on electrocardiogram (Figure 2) (Balser, 2001; Priori et al., 
2002a; Roden et al., 2002).  More than forty-three LQT3 variants have been 
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identified to date (Roden et al., 2002; Schram et al., 2002).  The 
electrocardiogram of LQT3 patients may have a distinct T-wave that is 
excessively far-away from the QRS complex compared to unaffected controls 
(Moss et al., 1995; Zareba, 2006).  The persistent Na+ current predisposes 
affected LQT3 patients with the possibility of ventricular tachycardia during sleep 
or periods of rest (Priori et al., 2001a). 
 In contrast, Nav1.5 variants leading to Nav1.5 loss-of-current may result in 
Brugada syndrome (Brugada and Brugada, 1995; Brugada and Brugada, 1992).  Gating 
defects in Brugada Syndrome variant channels can result in reduced Nav1.5 current 
(Brugada et al., 1998; Priori et al., 2002b).  The reduced Na+ current due to Brugada 
Syndrome variants can result in ventricular arrhythmias during periods of stress or 
exercise (Brugada et al., 1998; Priori et al., 2002b).  Patients with Brugada syndrome 
may present with periods of syncope or in the worst case, sudden death (Roden et al., 
2002).  Due to the difference in Nav1.5 expression in the ventricular wall, the 
electrocardiogram of Brugada Syndrome patients has an elevated ST fragment (Catterall 
et al., 2005; Roden et al., 2002).  The elevated ST fragment and T-wave inversions seen 
in Brugada syndrome patient electrocardiograms are commonly seen in patients with 
significant structural heart defects and are thought to be due to conduction defects 
(Antzelevitch et al., 2005).  However, Brugada syndrome patients are free of structural 
heart abnormalities (Antzelevitch et al., 2005).  Interestingly, disrupted Nav1.5 
expression is also one of the proposed mechanisms of disease for patients with Brugada 
syndrome (Priori et al., 2002). 
 
 
 
 12
Voltage-gated Na+ channels 
 
 The ultra-rapid entry of sodium into the ventricular myocyte through 
Nav1.5 causes a rapid change in the membrane potential that facilitates the 
activation and inactivation of other ion currents (Schram et al., 2002).  The 
velocity and amplitude of Nav1.5-dependent current overcomes the propensity of 
the cell to remain at rest (Bers, 2002; Hille, 2001).  In heart, the upstroke of the 
action potential is critical to reach the depolarized state that allows the activation 
of calcium-induced calcium-release (CICR) that drives the contraction of cardiac 
myofilaments (Bers, 2002).   
 Voltage-gated Na+ channels are composed of pore-forming alpha-subunits 
and accessory beta-subunits (Yu and Catterall, 2003).  There are nine voltage-
gated Na+ channel alpha-subunits (Nav1.1-1.9) (Yu and Catterall, 2003).  The 
primary cardiac voltage-gated Na+ channel alpha-subunit is Nav1.5 (Roden et al., 
2002).  There are four Nav beta-subunits (beta1-beta4) that may complex with 
alpha-subunits (Figure 3) (Yu and Catterall, 2003).  Human Nav1.5 is a 
glycosylated polypeptide comprised of 2016 amino acids with a predicted 
molecular mass of 260 kilodaltons (Balser, 2001; Yu and Catterall, 2003).  Nav1.5 
contains four homologous domains (DI-DIV), each comprised of six 
transmembrane alpha-helices (S1-S6) that are linked by cytosolic and 
extracellular loops (Figure 3) (Yu and Catterall, 2003).  Cytosolic amino- and 
carboxy-termini as well as inter-domain and inter-segment linkers comprise the 
cytosolic components of Nav1.5 (Balser, 2001; Yu and Catterall, 2003).  Inter-
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segment linkers including the pore-lining S5-S6 linkers make up the extracellular 
components of Nav1.5 (Balser, 2001; Yu and Catterall, 2003).  The extracellular 
and cytosolic loops connecting the transmembrane segments are critical for 
several processes including membrane localization, intermolecular interactions, 
and channel-gating activities (Balser, 2001; Yu and Catterall, 2003).  For 
example, the DIII-DIV linker is critical for inactivation of the channel (Balser, 
2001; Yu and Catterall, 2003).  Specific ion channel pore structures may be 
particularly sensitive to pharmacological substrates or even natural toxins (Lange 
et al., 2006a).  For example, several Nav channels are sensitive to the natural 
toxin tetrodotoxin (TTX) found in the Tetrodontidae family of fish (used to make 
the Japanese delicacy Fugu) (Yu and Catterall, 2003).  Specifically, multiple Nav 
channels are blocked by nanomolar concentrations of TTX (Yu and Catterall, 
2003).  Interestingly, unlike other voltage-gated Nav channels, Nav1.5 is blocked 
by TTX at 1-10µM (Balser, 2001; Yu and Catterall, 2003). This difference in TTX-
sensitivity between Nav isoforms is primarily attributed to a single amino acid 
(cysteine 373) in Nav1.5 transmembrane segment S6 (Balser, 2001; Yu and 
Catterall, 2003).  The unique TTX-sensitivity of Nav1.5 has proved valuable for 
differentiating Nav1.5 activity from other neuronal-type Nav1.X isoforms (Balser, 
2001; Yu and Catterall, 2003).   Voltage-gated Nav channel structure plays a key 
role for channel biophysical regulation.  For example, positively-charged arginine 
residues in the S4 (transmembrane segment-4) segments of each 
transmembrane domain comprise the Nav1.5 voltage-sensor (Balser, 2001; Yu 
and Catterall, 2003).  Specifically, these highly charged residues are arranged so 
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that upon membrane depolarization the S4 segments move through the lipid 
bilayer (Balser, 2001; Yu and Catterall, 2003).  This motion causes a change in 
Nav1.5 protein configuration and allows the permeation of Na+ (Balser, 2001).  
The structural properties of Na+ channel alpha-subunits together with the activity 
of modulatory molecules and accessory subunits regulate alpha-subunit gating 
properties (Balser, 2001).  Nav channel beta-subunits have a single 
transmembrane pass motif with an extracellular amino-terminus and a cytosolic 
carboxy-terminus (Figure 3) (Isom et al., 1995; Malhotra et al., 2001; Malhotra et 
al., 2000).  The extracellular motif of beta-subunits has similar characteristics to 
cell adhesion molecules, and is the site for covalent binding of beta2 and beta4 
subunits to neuronal Nav isoforms (Figure 3) (Isom et al., 1995; Malhotra et al., 
2001; Malhotra et al., 2000).  The cytosolic domains of beta1- and beta3-subunits 
contain a phosphorylation site hypothesized to be critical for interaction with 
cytoplasmic proteins (Malhotra et al., 2004).  The role of the beta-subunits in 
heart will be further discussed in Chapter 3.  
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Figure 3.  Voltage-gated Na+ channel alpha-subunit and accessory beta-
subunit.  Voltage-gated Na+ channel alpha-subunits are comprised of four six-
transmembrane domains with amino- and carboxy- termini.  Alpha-subunits are 
glycosylated at several sites (red circles) (Roden et al., 2002).  Accessory beta-
subunits have a cytosolic carboxy-terminus and an extracellular amino-terminus 
with immunoglobulin-like folds.  This figure was modified from Roden et al. 
Annual Review of Physiology 2002 (Roden et al., 2002). 
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 In addition to the channel pore-forming structure, additional transcriptional, 
post-transcriptional, and post-translational modifications and interactions 
modulate Nav channel function.  These include Nav1.5 mRNA splicing, 
phosphorylation, intermolecular interactions, glycosylation, trafficking, and 
neurohumoral regulation (Cusdin et al., 2008; Delisle et al., 2004; Herfst et al., 
2004).  The mechanisms that control the specific functional properties of Nav1.5 
(and other cardiac ion channels) remain an active area of research.   
  
Nav1.5 activity in non-cardiac tissues 
 
In addition to its role in regulation of cardiac function, recent findings 
illustrate that Nav1.5 has a number of unexpected non-cardiac functions.  
Specifically, Nav1.5 has been identified in smooth muscle cells of the uterus, 
endocytic macrophages, limbic regions of the brain, and the gastrointestinal tract 
(Abriel, 2007).  In uterine smooth muscle, Nav1.5 is important for regular and 
sustained contraction (Seda et al., 2007).  Specifically, Nav1.5 current initiates 
smooth muscle contraction by promoting calcium-induced calcium-release (Seda 
et al., 2007).  Recently, the unique expression of Nav1.5 in the endocytic vesicles 
of primary monocyte-derived macrophages was discovered (Carrithers et al., 
2007).  Nav1.5 is proposed to promote phagocytosis of bacteria and acidification 
of endocytic vesicles by proton flux (Carrithers et al., 2007).  In the limbic region 
of the brain (display high Nav1.5 expression) human probands with SCN5A 
variants display reduced GABAergic activity, and a high propensity for 
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schizophrenia (Roberts, 2006).  In the gastrointestinal tract, Nav1.5 is expressed 
in intestinal smooth muscle and the interstitial cell of Cajal, a specialized set of 
cells required for intestinal smooth muscle contraction (Strege et al., 2003).  
Interestingly, a recent study found patients with SCN5A variants with displayed 
increased likelihood for episodes of intestinal pain (Locke, 2006).  The cause of 
pain is hypothesized to result from prolonged contraction of intestinal smooth 
muscle cells due to persistent (increased) Nav1.5 current (Locke, 2006). 
 
Genetically-engineered Nav1.5 animal models 
 
 Studies of Nav1.5 knockout and transgenic animals demonstrate the 
importance of Nav1.5 (Papadatos et al., 2002).  Nav1.5 null (Nav1.5-/-) mice fail to 
develop beyond embryonic day 11, and have an irregular electrocardiogram 
(Papadatos et al., 2002; Royer et al., 2005).  Sections from Nav1.5-/- hearts show 
severe ventricular developmental defects (Papadatos et al., 2002).  Nav1.5 
heterozygous (Nav1.5+/-) mice display impaired action potential conduction 
velocity between the atria and ventricles (Papadatos et al., 2002).  Moreover, 
Nav1.5+/- mice are highly susceptible to the onset of fibrosis and development of 
conduction defects (Papadatos et al., 2002; Royer et al., 2005).  In fact, Nav1.5+/- 
mice phenocopy human disease termed Lev-Lenègre (a progressive human 
cardiac conduction disorder caused by SCN5A variants) (Royer et al., 2005).    
 Interestingly, in studies using a transgenic mouse model of Nav1.5 
overexpression (ten times the amount of Nav1.5 total protein), cardiomyocytes 
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from transgenic animals are electrophysiologically indistinguishable from wild-
type mice (Zhang et al., 2007).  These data suggest there are potential 
mechanisms that maintain the amount of Nav1.5 active at the membrane surface.  
One potential hypothesis is that there could be a finite amount of space available 
for Nav1.5 to fill at the membrane surface.  Alternatively, the excess Nav1.5 
remains inactive or fails to achieve the state of maturation necessary to be 
functionally expressed at the membrane surface.             
 
Alternative mechanisms of channelopathies 
 
 Recent findings have identified a new class of inherited cardiac arrhythmia 
based not on gene variants that may affect channel biophysics, but based 
instead on mutations that cause dysfunction in cellular pathways required for the 
proper localization of ion channels and transporters within the cardiomyocyte 
(Lehnart et al., 2007).  Several non-ion channel or ion channel subunit genes 
have been linked to cardiac channelopathies including; ankyrin-B (ANK2) , 
caveolin-3 (CAV3) (Cronk et al., 2007; Vatta et al., 2006; Yarbrough et al., 2002), 
glycerol phosphate-3-dehydrogenase 1-like protein (GPD1L) (London et al., 
2007; Van Norstrand et al., 2007), and calsequestrin (CASQ2) (Chopra et al., 
2007).  These new findings will be discussed in detail in Chapter 3.   
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CHAPTER II 
 
EXCITATION-CONTRACTION COUPLING AND  
 CARDIOMYOCYTE STRUCTURAL ORGANIZATION  
 
 
Cardiomyocyte structural organization 
  
 The proper expression, localization, and distribution of ion channels and 
transporters at subcellular and tissue-specific levels are critical for excitation-
contraction coupling (Schram et al., 2002).  The plasma membrane of myocytes 
is referred to as the sarcolemma (Lange et al., 2006b).  Contained within the 
muscle cell sarcolemma are a number of structural components that  support the 
activity of the contractile machinery (Lange et al., 2006b).  Muscle fibers, also 
called myofibrils, are composed of serially-connected structures that contain the 
myosin/actin contractile machinery (Lange et al., 2006b).  These structures are 
called sarcomeres (Lange et al., 2006b).  The border of each sarcomere is 
marked by a Z-disc (Lange et al., 2006b).  The Z-disc provides structural support 
for each sarcomere and acts as the anchor point for the actin-based thin 
filaments (Figure 4) (Lange et al., 2006b).  The Z-discs appear as an electron 
dense region on electron micrographs of myocytes (Figure 4) (Danowski et al., 
1992; Lange et al., 2006b).  Each Z-disc is surrounded by a lighter appearing 
region containing the actin-based thin filaments (Danowski et al., 1992; Lange et 
al., 2006b).  The Z-disc and the light region on both sides of each Z-disc is 
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referred to as the I-band (Figure 4, lower panel) (Danowski et al., 1992; Lange et 
al., 2006b).  Areas of contact between the sarcomere and the extracellular matrix 
are interspersed between Z-disc and act as points of force transmission between 
myocytes (Figure 4 upper panel) (Danowski et al., 1992; Lange et al., 2006a).  
These specialized areas surrounding the Z-disc are referred to as the 
costameres (Danowski et al., 1992). 
The M-band or M-line is the point where the myosin-based thick filaments 
are cross-linked by a protein complex (Figure 4) (Agarkova and Perriard, 2005).  
On either side of the M-band, myosin-based thick filaments extend from the 
center of the sarcomere toward the Z-discs (Figure 4) (Agarkova and Perriard, 
2005).  The region of the sarcomere containing the M-line and the thick filaments 
of myosin is referred to as the A-band (Figure 4, lower panel) (Agarkova and 
Perriard, 2005).  Together, the components of the sarcomere provide the 
structural framework for actin-myosin mediated contraction and relaxation 
(Agarkova and Perriard, 2005).       
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Figure 4.  Sarcomere organization.  Upper panel representation of myosin-rich 
thick filaments cross-linked at M-band. Actin-based thin filaments are attached to 
Z-disc.  Lower panel electron micrograph of sarcomere marked with Z-line, M-
band, I-band, and A-band.   Figure from Agarkova et al. (Liu et al., 2003).   
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Sarcolemmal organization 
 
Sarcolemma 
 The sarcolemmal membrane envelopes the intracellular content of the 
myocyte (Bers and Despa, 2006; Nerbonne and Kass, 2005; Roden et al., 2002).  
Moreover, the sarcolemmal membrane forms an electrically-insulated surface 
between intracellular and extracellular ion concentration gradients (Bers and 
Despa, 2006; Nerbonne and Kass, 2005; Roden et al., 2002).  Ion pumps, 
channels, and transporters maintain the “resting” ion concentration gradients and 
respond to stimuli upon excitation (Bers and Despa, 2006; Nerbonne and Kass, 
2005; Roden et al., 2002).  The sarcolemmal surface is populated with several 
ion channels (discussed in Chapter 1) and transporters including the Na+/Ca2+ 
exchanger (NCX), the Na+/K+ ATPase (NKA), the plasma membrane Ca2+ 
ATPase (PMCA), and the Na+/H+ exchanger (NHE) (Bers and Despa, 2006; 
Nerbonne and Kass, 2005; Roden et al., 2002).  The ion transporters NHE and 
NKA reduce the cytosolic Na+ content in response to the clearance of Ca2+ by 
NCX (1 Ca2+ ion out for 3 Na+ ions in) (Bers and Despa, 2006; Nerbonne and 
Kass, 2005; Roden et al., 2002). 
 
Transverse-tubule network 
 Specialized invaginations of the sarcolemmal membrane make up the 
transverse-tubule (T-tubule) membrane network (Agarkova and Perriard, 2005; 
Brette and Orchard, 2003; Lange et al., 2006a).  The T-tubule membrane 
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network has both transverse and thinner axial projections that project into the 
myocyte cell body (Figure 5) (Agarkova and Perriard, 2005; Brette and Orchard, 
2003; Lange et al., 2006a).  The T-tubules are populated with ion channels and 
transporters that are strategically juxtaposed to calcium release proteins of the 
sarcoplasmic reticulum (Agarkova and Perriard, 2005; Brette and Orchard, 2003; 
Lange et al., 2006a).  The larger diameter terminal opening of the T-tubules are 
localized along the Z-line (Agarkova and Perriard, 2005; Brette and Orchard, 
2003; Lange et al., 2006a).  The difference in diameter of the opening and distal 
branches of the T-tubule system provides temporal regulation of the excitation-
contraction cycle of the myocyte due to limited diffusion of ions in distal portions 
of the T-tubules (Agarkova and Perriard, 2005; Brette and Orchard, 2003; Lange 
et al., 2006a).  A specialized intracellular calcium storage and release system 
called the sarcoplasmic reticulum (described below) is located adjacent to 
sarcolemmal membrane domains (Agarkova and Perriard, 2005; Brette and 
Orchard, 2003; Lange et al., 2006a). 
Intercalated disc 
 Cardiomyocytes have a unique sarcolemmal membrane structure at their 
terminal ends called intercalated discs (ID) (Figure 5) (Awad et al., 2008; Perriard 
et al., 2003).  The intercalated discs provide intracellular and intercellular 
(adherens junctions) structural stability to the longitudinally-oriented contractile 
proteins (desmosomes) and the membrane elements of cardiomyocytes (Awad 
et al., 2008; Perriard et al., 2003).  The adherens junction proteins form contact 
points between cells at the intercalated discs (Awad et al., 2008; Perriard et al., 
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2003).  The adherens junctions are comprised of N-cadherin transmembrane 
proteins and cytosolic binding partners, alpha-catenin, beta-catenin, plakoglobin, 
and spectrin which attach the myofibrillary proteins (Awad et al., 2008; Perriard et 
al., 2003).   
 The desmosome provides structural stability between cell membranes and 
contractile proteins of adjacent cells, and has suggested roles in Ca2+ 
homeostasis and apoptotic signaling (Awad et al., 2008; Perriard et al., 2003).  
Desmosomes are comprised of desmocollin and desmoglein transmembrane 
proteins and plakoglobin and desmoplakin cytosolic proteins (Awad et al., 2008; 
Perriard et al., 2003).  These desmosomal cadherins help establish intercalated 
disc domains and provide stability to the desmin-rich intermediate filaments that 
cross-link the myofibrillary proteins (Awad et al., 2008; Perriard et al., 2003).  
Intercalated discs are also sites of cell-cell ion transport through gap junctions 
(Figure 5) (Awad et al., 2008; Perriard et al., 2003). 
 The primary gap junction protein in ventricular myocytes is connexin-43 
which forms a hexa-meric pore between the membrane of two adjoining cells 
(Petty and Lo, 2002).  The gap junctions, along with ion channels including 
Nav1.5, are localized to the intercalated discs and allow ion conduction between 
adjacent cells (Figure 5) (Petty and Lo, 2002).  Disruption of the gap junction 
proteins and intercalated discs are evidenced in patients with cardiomyopathic 
disease (Petty and Lo, 2002).    
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Figure 5.  Intercalated disc and transverse-tubule network membrane 
domains.   Inverted grayscale confocal image of two coupled adult rat 
cardiomyocytes.  Intercalated discs (ID) provide a mechanical and electrical 
junction between cardiomyocytes.  The transverse-tubule network (TTN and 
inset) is comprised of specialized sarcolemmal invaginations that facilitate the 
coordinated contraction along the length of cardiomyocytes. (Inset) Clusters of 
ion channels (DHPR) and transporters (Na+/Ca2+ exchanger, Na+/K+ ATPase, 
RyR, InsP3, SERCA 2A) expressed at sarcolemmal and sarcoplasmic 
membranes are placed proximally to regulate intracellular Ca2+ stores (adapted 
from Mohler et al. PloS 2005) (Mohler et al., 2005a). 
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Sarcoplasmic reticulum 
 
 The sarcoplasmic reticulum (SR) is a specialized intracellular organelle 
unique to myocytes (Figure 5, inset; grey membrane compartment).  The SR is 
the site of intracellular Ca2+ storage (10 times the content in the cytosol) in the 
cardiomyocyte (Bers and Despa, 2006).  The SR is populated with specialized 
calcium release channels including the ryanodine receptor (RyR) and the inositol 
1,4,5, trisphosphate receptor (IP3R) (Figure 5, inset) (Bers and Despa, 2006).  
The SR membrane also contains Ca2+ uptake transporters including the 
sarcoplasmic/endoplasmic reticulum calcium ATPase transporter and the 
SERCA2a inhibitory regulator phospholamban (not pictured) (Figure 5, inset) 
(Bers and Despa, 2006).  Phosphorylation of phospholamban removes the 
inhibition (reduced affinity for Ca2+) on SERCA2a and allows Ca2+ to be loaded 
into the SR and cleared from the cytosol (Bers and Despa, 2006).  Maintenance 
of the intracellular ion content is critical for normal physiological activity and in 
prevention of disease (Bers and Despa, 2006).  
 
Excitation-contraction coupling 
 
 As described above, the vertebrate cardiomyocyte contains a number of 
structural, electrical, and signaling components.  These components collaborate 
to modulate the functional activity of the myocyte.  This process, that translates 
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electrical stimulation with mechanical force to generate cellular contraction, 
relaxation, and thus cardiac function is termed excitation-contraction coupling.   
 Excitation-contraction coupling is initiated by the rapid entry of Na+ into the 
cardiomyocyte at phase 0 (Figure 2) through Nav1.5.  This initial event drives the 
depolarization of the myocyte, and triggers the activation of voltage-gated Ca2+ 
channels (Cav1.2) along the T-tubule membrane network (Ohtsuki and Morimoto, 
2008).  Cav1.2 channels are closely juxtaposed to specialized calcium-release 
channels on the SR termed ryanodine receptors (RyR) (Ohtsuki and Morimoto, 
2008).  This specialized juxtaposition of external and internal membranes is 
referred to as the “dyad” (Ohtsuki and Morimoto, 2008).  Cellular depolarization 
causes calcium-influx through Cav1.2 resulting in an increase in local cytosolic 
Ca2+ (10-20 µM) within the dyad (Endoh, 2006; Ohtsuki and Morimoto, 2008).  
This elevation in local Ca2+ subsequently triggers calcium-induced calcium-
release from internal SR stores via the RyR (Endoh, 2006; Ohtsuki and 
Morimoto, 2008).  Once cytosolic Ca2+  reaches a threshold of  10-6 – 10-5 M, 
Ca2+ binds and activates troponin-C, resulting in the inhibitory release of 
actin/tropomyosin-based thin filaments by troponin-I (Endoh, 2006; Ohtsuki and 
Morimoto, 2008).  Following release from troponin-I, thin-filaments form cross-
bridges with myosin-based thick filaments and generate force due to filaments 
sliding over each other to shorten the sarcomere (Endoh, 2006; Ohtsuki and 
Morimoto, 2008).  Following contraction, the activation of Na+/Ca2+ exchanger, 
SERCA2a, and plasma membrane Ca2+ ATPase (PMCA) Ca2+ efflux pathways 
restore cytosolic Ca2+ concentrations to pre-contraction levels (Endoh, 2006; 
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Ohtsuki and Morimoto, 2008).  Once cytosolic [Ca2+]i are restored to diastolic 
levels, cross-bridge formation, and the affinity of troponin-C for Ca2+ is reduced 
resulting in sarcomere filamentary relaxation (Endoh, 2006; Ohtsuki and 
Morimoto, 2008).   
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CHAPTER III 
 
VOLTAGE-GATED SODIUM CHANNEL-ASSOCIATED PROTEIN ACTIVITY 
AND MEMBRANE BIOGENESIS  
 
 
Regulation of Nav channel expression 
Control of Nav channel expression is an intricate process that requires a 
series of incompletely understood transcriptional, translational, and post-
translational mechanisms (Abriel, 2007; Herfst et al., 2004).  Transcription is 
tightly controlled by the association of transcription factors and mechanisms that 
modify the accessibility of DNA (Abriel, 2007; Cusdin et al., 2008; Herfst et al., 
2004).  Newly translated Nav1.5 is inserted into the ER under the guidance of 
specific signal sequences that bind signal recognition particles that target the 
nascent protein to receptors on the ER (Abriel, 2007; Cusdin et al., 2008; Herfst 
et al., 2004).  Once nascent Nav1.5 is inserted into the ER there are several 
chaperone molecules that are thought to associate and provide quality control 
and guidance for folding and maturation of the protein (Delisle et al., 2004).  The 
membrane topology of Nav1.5 is critically important because the multi-
transmembrane pass motifs are interspersed with specific cytoplasmic and 
extracellular functional elements (Delisle et al., 2004).  Once inserted into the 
ER, Nav1.5 is core glycosylated as cellular quality control machinery ensures that 
the protein is properly folded (Delisle et al., 2004).  Misfolded proteins that fail 
quality control measures are marked for degradation by proteasomal or 
lysosomal machinery (Delisle et al., 2004).  Proper protein folding is thought to 
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mask ER retention motifs which allow the nascent Nav1.5 to be trafficked through 
the ER-Golgi intermediate compartment to the Golgi (Cusdin et al., 2008).  Once 
Nav1.5 is in the Golgi, several rounds of glycosylation drive the maturation of the 
protein (Cusdin et al., 2008).  The matured Nav1.5 is then sent to the Trans-Golgi 
network for sorting and determination of the final destination of the protein 
(Cusdin et al., 2008; Delisle et al., 2004).  The molecular chaperones and 
cytosolic signal sequences on Nav1.5 and molecules that complex with these 
motifs are thought to guide the efflux of Nav1.5 to the proper intracellular 
destination, however the specific mechanisms that control ion channel and 
transporter traffic to the membrane remain unresolved (Cusdin et al., 2008; 
Delisle et al., 2004).  Nav1.5 and other excitable-cell proteins that reach the 
sarcolemmal membrane are assembled into respective complexes and are often 
anchored to specific membrane domains (Cusdin et al., 2008).  Integral 
membrane proteins are often recycled or turned over by the endosomal proteins 
that can signal the proteins for degradation or recycling back to the membrane 
(Abriel and Kass, 2005).  Several molecules are suggested to interact with 
Nav1.5 and modulate channel biophysical activity or membrane expression 
(Abriel, 2007; Abriel and Kass, 2005). 
 
Proposed interacting/targeting proteins 
 
 Recent studies have suggested that Nav1.5 interacts with diverse 
molecules to modulate membrane trafficking (Cusdin et al., 2008).  Molecules 
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with proposed importance for localization of ion channels have been suggested 
to interact with Nav1.5 including Nav beta-subunits (SCN1B-SCN4B) (Isom et al., 
1995; Malhotra et al., 2001; Malhotra et al., 2000; Malhotra et al., 2002; Malhotra 
et al., 2004; Yu and Catterall, 2003), syntrophins (SNTA1, SNTB1, SNTB2) 
(Gavillet et al., 2006b; Ou et al., 2003), and Nedd-4-like ubiquitin ligase (NEDD4-
2) (Rougier et al., 2004; van Bemmelen et al., 2004).  Additionally, molecules 
with poorly defined or unknown physiological function have also been suggested 
to change the membrane expression of Nav1.5 including glycerol phosphate-3-
dehydrogenase 1-like protein (GPD1L) (London et al., 2007b; Van Norstrand et 
al., 2007a), and ran guanine nucleotide release factor (MOG1) (Wu et al., 2008).  
The following section will review these proposed interacting molecules and their 
potential roles in regulating Nav1.5 membrane targeting. 
 The contribution of Nav beta-subunits to modify channel gating kinetics 
and localization of Nav1.5 has conflicting reports in the literature from studies in 
different cell types (Maier et al., 2004).  All four Nav beta-subunit genes (SCN1B-
SCN4B) are reported to be expressed in heart (Maier et al., 2004; Meadows and 
Isom, 2005).  Navbeta-2, Navbeta-1, and Navbeta-4 subunits are reported to be 
expressed at the intercalated disc and Navbeta-1 and Navbeta-3 along the T-
tubules (Maier et al., 2004).  The phosphorylation state of Navbeta-subunit 
isoforms (1 and 3) is reported to be important for association with ankyrin 
proteins (Malhotra et al., 2004).  Navbeta-1 at the intercalated disc is 
phosphorylated and cannot interact with ankyrin-G (Malhotra et al., 2004).  In 
contrast, Navbeta-1 along the T-tubules is non-phosphorylated and is suggested 
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to interact with similar ankyrin-B (Malhotra et al., 2004).  The Navbeta-1 subunits 
at the intercalated disc are suggested to stabilize the intercalated disc by 
complexing with N-cadherin and connexin 43 (Lopez-Santiago et al., 2007).  
However, studies of cardiomyocytes from Navbeta-1-knockout mice show that 
reduction of Navbeta-1 subunit expression does not reduce expression or 
membrane stability of Nav1.5, connexin 43, or N-cadherin (Lopez-Santiago et al., 
2007).  Interestingly, the expression and activity of Nav1.5 is increased in 
Navbeta-1 knockout cardiomyocytes, however it is noteworthy that the knockout 
mice have severe neurological defects (Lopez-Santiago et al., 2007).  These 
data show that despite the similarities in Nav channel trafficking in neurons and 
cardiomyocytes, the specific channel isoform and cellular context is critical when 
studying trafficking mechanisms (Chen et al., 2002).  Cardiomyocytes from a 
knockout model of Navbeta-2 display no discernable phenotype in the activity or 
expression of Nav1.5 in the heart, but the activity and expression of neuronal Nav 
channels was disrupted in the brain (Chen et al., 2002).  The functions of 
Navbeta-3 and Navbeta-4 have not been demonstrated in vivo however SCN4B 
variants (gene that encodes Navbeta-4) are linked with a family of LQT3 patients 
(Kahlig et al., 2006).  Recent studies have identified variants in SCN1B (encodes 
Navbeta-1) that have been linked to both neuronal (epilepsy) and cardiac 
(Brugada syndrome) arrhythmic disease (Watanabe et al., 2008).  However, due 
to the contradicting information from studies using different cell systems and the 
lack of animal models for all Navbeta-subunits, the specific role of Navbeta-
subunits remains unresolved in heart.  Chapter 6 will revisit and propose future 
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experiments to address the role for Navbeta subunits and ankyrins with respect to 
Nav channel targeting in the heart. 
 Co-immunoprecipitation experiments showed the association of Nav1.5 
and alpha- and beta-Syntrophins (SNTA1, SNTB1, SNTB2) (Gavillet et al., 
2006a; Ueda et al., 2008).  Alpha- and beta-syntrophins are hypothesized to 
provide a link between the dystrophin complex and the PDZ-binding domain in 
the carboxy-terminus of Nav1.5 (Gavillet et al., 2006a; Ueda et al., 2008).  
Removal of the PDZ-binding domain blocked the interaction of Nav1.5 and the 
dystrophin complex (Gavillet et al., 2006b).  These experiments were conducted 
in the context of a dystrophin-deficient mouse and showed a significant reduction 
in Nav1.5 protein expression (immunoblot) and surface current density (Gavillet 
et al., 2006b).  However these studies failed to show the specific contribution of 
the syntrophin isoforms for Nav1.5 localization or physiological function.  Future 
studies are needed to define the physiological relevance of syntrophin isoforms 
for Nav1.5 activity and localization.  
 Nedd4-like ubiquitin ligase (NEDD4-2) is a member of the E3 protein-
ubiquitin ligase family of enzymes that bind and ubiquitinate target proteins at 
specific sites (PY-motif, PPXY) that mark proteins for degradation by the 
proteasome (Rougier et al., 2004; van Bemmelen et al., 2004).  The carboxy-
terminus of Nav1.5 contains a PY-motif known to bind E3 protein-ubiquitin ligases 
like Nedd4-2 (Rougier et al., 2004; van Bemmelen et al., 2004).  Heterologous 
cells expressing Nav1.5 down-regulate INa upon overexpression of Nedd4-2 
(Rougier et al., 2004; van Bemmelen et al., 2004).  There is also biochemical 
 37
evidence that Nav1.5 is ubiquitinated in vivo (Rougier et al., 2004; van Bemmelen 
et al., 2004).  However these studies fail to represent the extent of Nav1.5 
internalization and degradation due to Nedd4-2 activity and the physiological 
importance of the Nedd4-2-based pathway.   
 Glycerol phosphate-3-dehydrogenase 1-like protein (GPD1L) is a protein 
of unknown function that has been linked to Brugada Syndrome and sudden 
infant death syndrome using mutational analyses (London et al., 2007b; Van 
Norstrand et al., 2007a).  GPD1L variants expressed in heterologous cells 
(HEK293 and COS-7) or in transduced neonatal mouse cardiomyocytes result in 
reduction of sodium current density (London et al., 2007b; Van Norstrand et al., 
2007a).  However, the specific physiological effect of GPD1L transduction is 
undefined as well as the primary function of the protein (London et al., 2007b; 
Van Norstrand et al., 2007a).  Trafficking studies in heterologous cells suggest 
that GPD1L may effect the proper cellular localization of Nav1.5 (London et al., 
2007b; Van Norstrand et al., 2007a).  However, the physiological function of 
GPD1L remains unresolved.  Moreover, determining the physiological function 
and potential Nav1.5 trafficking role of GPD1L would benefit from the 
development of a transgenic animal model or other reduction/reconstitution 
strategies. 
 Ran-guanine nucleotide release factor (MOG1) was identified as an 
interacting partner of Nav1.5, using the DII-DIII linker of Nav1.5, in yeast two-
hybrid analyses (Wu et al., 2008).  Subsequent in vitro binding analyses and co-
immunoprecipitation experiments demonstrated that MOG1 and Nav1.5 associate 
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(Wu et al., 2008).  Overexpression of MOG1 resulted in a gain in INa density in 
both HEK293 cells co-expressing Nav1.5 and neonatal cardiomyocytes (Wu et 
al., 2008).  The authors also failed to provide any data demonstrating the 
physical expression of increased Nav1.5 at the membrane (Wu et al., 2008).  
Biochemical analyses of HEK293 cells overexpressing Nav1.5 and MOG1 had 
increased Nav1.5 in the membrane fraction of lysates (Wu et al., 2008).  These 
results are interesting, however they would benefit from further analyses in more 
physiological contexts such as primary cardiomyocytes (Wu et al., 2008) .  
Moreover, the specific mechanism that MOG1 may play on Nav1.5 activity 
(increase in surface expression or channel gating) and the primary biochemical 
function of MOG1 remain unknown.  These studies would benefit from the 
development of a transgenic animal model or other reduction/reconstitution 
system to determine the function of MOG1. 
 In summary, although several proteins interact with Nav1.5 and possibly 
modify membrane targeting, the specific mechanisms and contributions of the 
interaction partner proteins to these processes remain unclear.  
 
Proposed interacting/modulatory proteins 
 
 Several proteins have been discovered to interact and possibly modulate 
the biophysical activity of Nav1.5 (Abriel, 2007).  Calmodulin (CALM1) interacts 
with the carboxy-terminus of Nav1.5 and has been linked to the regulation of 
other ion channels (Kim et al., 2004; Maltsev et al., 2008; Shah et al., 2006; Tan 
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et al., 2002; Wingo et al., 2004).  The primary cardiac caveolin-family member, 
caveolin-3 (CAV3) is reported to interact with Nav1.5 (Cronk et al., 2007; Vatta et 
al., 2006; Yarbrough et al., 2002).  Fibroblast growth factor homologous factor 1B 
(FHF1B) has also been suggested to interact with Nav1.5 (Liu et al., 2003).  
Several signaling proteins including, protein tyrosine phosphatase, non-receptor 
type 3 (PTPH1) (Jespersen et al., 2006), Src-family protein tyrosine kinase, Fyn 
(FYN) (Ahern et al., 2005), and tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase activation protein (14-3-3) (Allouis et al., 2006).   
 Calmodulin (CALM1) binds an IQ motif on the carboxy-terminal tail of 
Nav1.5 (Shah et al., 2006; Wingo et al., 2004).  Data from structural analyses and 
heterologous co-expression studies suggest that calmodulin interacts with the 
inactivation gating structures of Nav1.5 and modify channel availability in 
response to Ca2+ (Shah et al., 2006; Wingo et al., 2004).  The results from these 
studies have been conflicting regarding the specific form and state of inactivation 
affected, or not, by calmodulin (Maltsev et al., 2008; Tan et al., 2002).  Recent 
studies in failing dog heart, and in TSA201 cells, show that the presence of Ca2+ 
and excess calmodulin results in a hyperpolarizing shift in the steady-state 
inactivation curve of Nav1.5 (Maltsev et al., 2008; Tan et al., 2002).  The authors 
suggest that the presence of Ca2+ and excess calmodulin increases the slow 
component of inactivation (Maltsev et al., 2008; Shah et al., 2006; Wingo et al., 
2004).  However, conflicting data has been described in rabbit cardiomyocytes 
and other heterologous cell systems (Wagner et al., 2006).  Therefore, the exact 
role that calmodulin plays in regulating Nav1.5 remains a topic of debate.  
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Furthermore, the specific molecular mechanism, Ca2+ binding state (bound or 
unbound), and the conformation of the inactivation gating structure required for 
calmodulin to bind Nav1.5 remain unresolved. 
 Caveolin-3 (CAV3) is the primary form of caveolin in striated muscle cells 
(Westermann et al., 2005).  CAV3 variants have been linked to both LQT3 and 
sudden infant death syndrome (Cronk et al., 2007; Vatta et al., 2006).  Caveolin-
3 knockout mice do not have a significant difference with respect to Nav1.5 
phenotype, however the mice develop severe cardiomyopathy (Park et al., 2002).  
One study showed that Nav1.5 was enriched in the caveolin-3-rich detergent-free 
density centrifugation membrane fraction (Yarbrough et al., 2002).  However, it is 
important to note that whether caveolin-3 directly interacts with Nav1.5 has yet to 
be experimentally determined.  Co-expression studies of CAV3 and Nav1.5 in 
heterologous cells resulted in persistent INa (Cronk et al., 2007; Vatta et al., 
2006).  Further analyses in myocytes suggest that Nav1.5 rich caveolae increase 
INa density in response to beta-adrenergic signaling through the G-protein 
GSalpha (Palygin et al., 2008).  Moreover, the physiological-state where caveolin-
3-linked Nav1.5 current modulation is required is yet to be determined.   
 Fibroblast growth factor homologous factor 1B (FHF1B) associates with 
the carboxy-terminus of Nav1.5 as revealed by yeast two-hybrid analysis and co-
immunoprecipitation from heterologous cell lysates over-expressing human 
Nav1.5 fusion protein (Liu et al., 2003).  HEK293 cells expressing Nav1.5 and 
FHF1B did not have any change in activation however, there was a -9mV 
(hyperpolarizing) shift in inactivation (Liu et al., 2003).  Heterologous co-
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expression of a LQT3 (SCN5A) variant D1790G, blocked this electrophysiological 
affect and the in vitro binding of FHF1B (Liu et al., 2003).  However, the 
physiological importance of FHF1B activity has not yet been demonstrated.  
Moreover, the nature of the interaction of FHF1B and Nav1.5 is poorly 
understood.  Additionally, there are no diseases currently linked to variants in 
FHF1B.  Therefore, the physiological importance of FHF1B in regulating Nav1.5 
remains unknown. 
 Protein tyrosine phosphatase, non-receptor type 3 (PTPH1) is proposed to 
interact with Nav1.5 as suggested by in vitro binding and pull-down analyses 
(Jespersen et al., 2006).  The carboxy-terminus of Nav1.5 has a PDZ-binding 
domain motif that was shown to be critical for interaction with PTPH1 in this study 
(Jespersen et al., 2006).  Co-expression studies of PTPH1 with Nav1.5 in 
HEK293 cells causes a hyperpolarizing shift in steady-state inactivation however, 
there is no affect on channel activation (Jespersen et al., 2006).  Experiments 
with PTPH1 were complemented by the use of constitutively active Fyn, a protein 
tyrosine kinase (Jespersen et al., 2006).  Co-expression studies incorporating 
constitutively active Fyn suggest that phosphorylation changes the stability of the 
inactivation gate, and shifts inactivation to more positive potentials (Ahern et al., 
2005).  However the physiological importance of the contrasting activities of 
PTPH1 and protein tyrosine kinase Fyn has not yet been demonstrated.          
 Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation 
protein (14-3-3) was identified as an interacting protein using the cytoplasmic 
interdomain linker (DI-DII) of Nav1.5 in a yeast two-hybrid screen (Allouis et al., 
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2006).  14-3-3η was effectively co-immunoprecipitated with Nav1.5 from 
heterologous cells expressing Nav1.5 and mouse heart lysates (Allouis et al., 
2006).  Co-expression experiments demonstrated that 14-3-3η caused a 
hyperpolarizing shift in inactivation and increased the time for recovery from 
inactivation (Allouis et al., 2006).  These studies suggest that 14-3-3η can modify 
the availability of Nav1.5 and the kinetics of channel activity (Allouis et al., 2006).  
However, the physiological importance or effect of 14-3-3η with regard to Nav1.5 
activity is yet to be determined and requires the development of transgenic 
animal models to deductively address these questions. 
 The complex regulatory mechanisms that control the biophysical activity 
and membrane targeting of Nav1.5 are the focus of research in several labs 
around the world.  Further investigation of these potential interaction proteins will 
provide important clues in understanding these complex regulatory mechanisms.   
Interestingly, ankyrin family proteins have been linked to the membrane activity 
of other channels and transporters as well as Nav1.5.   The ankyrin family of 
proteins will be discussed in Chapter IV.  
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CHAPTER IV 
 
ANKYRINS AND DISEASE 
 
Ankyrins are a family of multivalent membrane-adaptor proteins first 
identified in the erythrocyte over twenty five years ago as a link between the 
anion exchanger and the spectrin-based cytoskeleton.  Since their initial 
discovery, ankyrin function has been linked to protein targeting and membrane 
domain organization in a variety of cell-types including erythrocytes, neurons, 
epithelial cells, and cardiomyocytes.  Recent findings demonstrate that 
dysfunction in ankyrin-based cellular pathways in heart may lead to human 
ventricular tachycardia and sudden cardiac death.  
Specifically, mutations in ankyrin-based cellular pathways potentially lead 
to two cardiac arrhythmia syndromes including ‘ankyrin-B syndrome’, an atypical 
long QT syndrome (previously referred to as type 4 long QT syndrome) and 
Brugada syndrome (Lowe et al., 2008; Mohler et al., 2004; Mohler et al., 2003b).  
This chapter will provide a general description of the ankyrin family and detail 
recent findings implicating key roles for ankyrin-based cellular pathways in 
normal cardiac function.   
 
Ankyrins:  Required for membrane protein targeting 
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      Ankyrins are a family of ubiquitously-expressed membrane-adaptor 
proteins required for targeting structurally-unrelated ion channels, transporters, 
and cell adhesion molecules to specialized membrane domains (reviewed in 
(Bennett and Baines, 2001)).  Human ankyrin polypeptides including ankyrin-R 
(for ‘restricted’), ankyrin-B (for ‘broad’), and ankyrin-G (for ‘giant’ or ‘general’) are 
encoded by three unique genes localized to human chromosomes 8p11 (ANK1), 
4q25-27 (ANK2), and 10q21 (ANK3), respectively.  While present in other 
metazoans including Drosophila (two genes Dank1, Dank2) and Caenorhabditis 
elegans (one gene, unc-44), ankyrins have not been identified in the genomes of 
lower organisms including yeast (Saccharomyces cerevisiae, or 
Schizosaccharomyces pombe).  Canonical ankyrins (210 kDa ankyrin-R, 220 
kDa ankyrin-B, and 190 kDa ankyrin-G) have four major domains including a 
large NH2-terminal membrane-binding domain, a central spectrin-binding domain, 
a death domain, and a C-terminal regulatory domain (Figure 6).  
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Figure 6. 
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Figure 6.  Canonical ankyrin polypeptide domain organization.  Ankyrins 
contain a NH2—terminal membrane-binding domain comprised of 24 
\consecutive ANK repeats (blue), a spectrin-binding domain (green), a death 
domain (red), and a C-terminal regulatory domain. 
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  The ankyrin membrane-binding domain is comprised of 24 consecutive 
ANK repeats (a 33 amino acid protein interaction domain; (Sedgwick and 
Smerdon, 1999).  Together, these ANK repeats create a large super-helix which 
creates binding sites for a variety of structurally-diverse membrane proteins.  
Characterized ankyrin-binding proteins include ion channels and transporters of 
the plasma membrane (Na/K ATPase (Koob et al., 1988; Morrow et al., 1989), 
Na/Ca exchanger (Li et al., 1993), anion exchanger (Bennett and Stenbuck, 
1979b; Jons and Drenckhahn, 1998),  H/K ATPase (Morgans and Kopito, 1993), 
voltage-gated Nav channels (Srinivasan et al., 1988), ammonium transporter 
(Lopez et al., 2004), and endoplasmic/ sarcoplasmic reticulum (inositol 1, 4, 5 
trisphosphate receptor, ryanodine receptor; (Mohler et al., 2005a); Figure 7). 
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Figure 7. 
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Figure 7. Ankyrins associate with diverse membrane-associated, 
cytoskeletal, and cytosolic proteins. 
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The ankyrin membrane-binding domain also associates with cell adhesion 
molecules including L1 cell adhesion molecules (L1CAMs; (Davis and Bennett, 
1994) ) and CD44 adhesion molecules ((Lokeshwar et al., 1994); Figure 7).  The 
central 62 kDa domain of ankyrin contains binding activity for the beta-spectrin 
family of actin-binding proteins (Bennett and Stenbuck, 1979a).  Ankyrin/beta-
spectrin interactions are critical for normal physiological function of multiple cell 
types including erythrocytes (Bennett and Baines, 2001).  Identification of 
additional roles for this large domain is an active area of ankyrin research as 
recent findings suggest a key role for the C-terminus of the spectrin-binding 
domain in ankyrin-B-dependent function in human heart (described below).  In 
addition to membrane-binding and spectrin-binding domains, ankyrins display a 
90 amino acid death domain of unknown function (Figure 6).  Based on the ability 
of death domain secondary structures to form low affinity homo- or hetero-
dimers, this domain may be responsible for facilitating the formation of large 
complexes of ankyrin multimers in cellular environments where ankyrin 
concentrations are extremely high.  Finally, canonical ankyrins express a C-
terminal regulatory domain (Figure 6).  This region is the most divergent between 
ankyrin gene products suggesting a critical role for this domain in specifying 
gene-specific function in vivo.  The recent identification of nine different loss-of-
function mutations in the ankyrin-B C-terminus associated with human cardiac 
arrhythmia (described below) further supports a key role for this domain for 
ankyrin-specific function.  Based on in vitro experiments, ankyrin C-terminal 
domains have been predicted to associate in vivo with diverse cytoplasmic 
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proteins including the molecular co-chaperone Hdj1/Hsp40 (Mohler et al., 2004b) 
and obscurin (Bagnato et al., 2003)  and the large myofibrillar protein titin 
(Kontrogianni-Konstantopoulos and Bloch, 2003) . 
 
‘Ankyrin-B Syndrome’ A new class of cardiac arrhythmia 
 
 Autosomal-dominant type 4 long QT syndrome was first characterized in a 
large French kindred by Schott et al. in 1995 (Schott et al., 1995).  Patients with 
this syndrome display a complex cardiac phenotype including sinus bradycardia, 
abnormal heart rate variability, defects in cardiac repolarization (denoted on the 
ECG as prolonged QT interval), and sudden cardiac death (Mohler et al., 2003).  
Schott et al. used the large French kindred to map the cardiac syndrome to 
human chromosome 4q25-27 (Schott et al., 1995), a site unique from genes 
previously implicated in congenital long QT syndrome.  Nearly eight years later, a 
nucleotide variant was identified in the gene encoding ankyrin-B (ANK2), a non-
ion channel,  in affected family members of the original type 4 long QT syndrome 
kindred (Mohler et al., 2003).  This single nucleotide transition (A-to-G transition 
at position 4274) was not present in non-affected family members, and was not 
present in a human control population which displayed normal 
electrocardiograms (Mohler et al., 2003).  The single A4274G transition results in 
the change of a conserved glutamic acid-to-glycine in the C-terminus of the 220 
kDa ankyrin-B spectrin-binding domain (E1425G; Figure 8).  
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Cardiomyocytes derived from mice heterozygous for a null mutation in ankyrin-B 
(ankyrin-B+/- mice) were utilized to determine whether the E1425G variant was an 
ankyrin-B loss-of-function mutation.  While mice homozygous for a null mutation 
die shortly after birth, ankyrin-B+/- mice live to adulthood with ~50% reduction of 
220 kDa ankyrin-B in heart (Mohler et al., 2003).  Interestingly, ankyrin-B+/- mice 
share a number of common phenotypes with humans with type 4 long QT 
syndrome (both humans with ankyrin-B-syndrome and ankyrin-B+/- mice express 
~50% of normal ankyrin-B) including sinus bradycardia, significant variability in 
heart rate, aberrant cardiac conduction (both depolarization and repolarization), 
stress- or exercise- induced polymorphic ventricular tachycardia, and sudden 
cardiac death (Mohler et al., 2003).  Ankyrin-B+/- neonatal cardiomyocytes display 
approximately 50% reduction in levels of 220 kDa ankyrin-B (Mohler et al., 
2002a; Mohler et al., 2003).  Ankyrin-B+/- neonatal cardiomyocytes also exhibit 
significant abnormalities in spontaneous contraction rates and display abnormal 
cytosolic calcium transients (Mohler et al., 2003; Mohler et al., 2004d).  At a 
molecular level, ankyrin-B+/- neonatal cardiomyocytes display abnormal 
localization and expression of Na/K ATPase, inositol 1, 4, 5 trisphosphate 
receptor (InsP3 receptor), and Na/Ca exchanger (all ankyrin-binding proteins) 
while other cardiomyocyte structural proteins and ion channel/transporters 
(including Nav1.5) are normally expressed and appropriately localized (Mohler et 
al., 2002b).  Abnormal ankyrin-B+/- cardiomyocyte phenotypes, including 
contraction rates, calcium dynamics, and channel/transporter localizations are 
rescued by expression of GFP-220 kDa ankyrin-B but not GFP-190 kDa ankyrin-
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G (Mohler et al., 2002a).  Therefore, abnormal cellular phenotypes observed in 
ankyrin-B+/- neonatal cardiomyocytes are due to monogenic loss of ankyrin-B 
expression.  Moreover, these results demonstrate that ankyrin-B and ankyrin-G 
polypeptides have non-redundant roles for ion channel and transporter targeting 
in heart (Mohler et al., 2002a).  More importantly, these data indicated that 
ankyrin-B+/- neonatal cardiomyocyte rescue system could be used to test 
potential ankyrin-B loss-of-function mutations.   
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Figure 8. 
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Figure 8. Spectrum of ankyrin-B loss-of-function mutations associated with 
human polymorphic ventricular tachycardia. Figure from Mohler et al. 
Circulation 2007.  
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 GFP-220kDa ankyrin-B E1425G has similar localization and expression to 
GFP-220 kDa ankyrin-B, and therefore likely does not represent a structural 
mutation (Mohler et al., 2003; Mohler et al., 2004d).  However, in contrast to 
GFP-220 kDa ankyrin-B, expression of GFP-220 kDa ankyrin-B E1425G does 
not rescue abnormal spontaneous contraction rates, abnormal calcium dynamics, 
or abnormal ion channel and transporter localizations in ankyrin-B+/- 
cardiomyocytes (Mohler et al., 2004d).  These results demonstrate that the 
E1425G mutation associated with cardiac arrhythmia is a loss-of-function 
mutation in cardiomyocytes.  These data represented the first evidence for a new 
class of cardiac arrhythmia due to a mutation of a non-ion channel or associated 
subunit.  Since the ankyrin-B E1425G mutation is localized near the C-terminus 
of the spectrin-binding domain (see Figure 8), it is unlikely to interfere with 
ankyrin-B binding activity for membrane proteins (binding sites in N-terminal 
membrane-binding domain).  Therefore, this mutation may block binding of 
ankyrin-B to a specific regulatory protein or represent a key regulatory site for 
ankyrin-B-specific function (multiple potential phosphorylation sites near E1425).  
The molecular mechanism underlying the E1425G mutation is an active area of 
research by multiple ankyrin laboratories. 
 Since the initial identification of the E1425G ankyrin-B loss-of-function 
mutation, four additional loss-of-function mutations have been identified in 
humans with polymorphic ventricular tachycardia (Mohler et al., 2004d).  
Interestingly, all of these mutations are localized in the divergent ankyrin-B C-
terminal regulatory domain (Figure 8; L1622I, T1626N, R1788W, E1813K) 
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(Mohler et al., 2004d).  Like the E1425G mutation, the underlying molecular 
consequences of the new ankyrin-B mutations are unknown and a current focus 
of our lab.  
Cardiomyocytes derived from adult ankyrin-B+/- mice display normal action 
potentials (Mohler et al., 2003).  These results are consistent with the normal 
expression and localization of voltage-gated Nav channels, K+ channels, and 
voltage-gated Ca2+ channels in ankyrin-B+/- adult cardiomyocytes (Mohler et al., 
2003).  However, cardiomyocytes derived from adult ankyrin-B+/- mice display 
aberrant elevated calcium transients (Mohler et al., 2003).  Elevations in ankyrin-
B+/- calcium transients are explained by the reduction and abnormal localization 
of both Na/K ATPase and Na/Ca exchanger in these cells (Mohler et al., 2004a).  
Reduced Na/K ATPase expression would elevate intracellular Na+ levels and 
further reduce the activity of the Na/Ca exchanger (expression already reduced 
in ankyrin-B+/- cells).  Reduced Na/Ca exchanger activity reduces calcium export.  
Consequently, excess calcium is pumped into internal stores leading to 
increased sarcoplasmic reticulum calcium load and elevations in calcium 
transients.  Elevations in calcium transients may lead to the observed early and 
delayed after-depolarizations and extra-systoles when ankyrin-B+/- cells are 
stimulated with isoproterenol (Mohler et al., 2004d).  Therefore, ventricular 
arrhythmia due to ankyrin-B dysfunction in humans is likely a direct result of 
calcium-induced spontaneous depolarization episodes in the face of 
catecholaminergic stimulation.   
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 Recently identified probands with ankyrin-B loss-of-function mutations are 
redefining type 4 long QT syndrome as a new cardiac syndrome distinct from 
classic long QT syndromes.  New probands with E1425G, L1622I, T1626N, 
R1788W, and E1813K mutations display cardiac phenotypes similar, but not 
identical to the original French kindred (Mohler et al., 2004d; Zhang et al., 2004).  
For example, probands with ankyrin-B mutations may present with cardiac 
arrhythmia with sinus bradycardia, atrial fibrillation, idiopathic ventricular 
fibrillation, and polyphasic T waves (Mohler et al., 2004d; Zhang et al., 2004).  
However, unlike the original French kindred, not all probands or affected family 
members display significant QTc abnormalities (Mohler et al., 2004d; Schott et 
al., 1995; Zhang et al., 2004).  While this syndrome is distinct from classic long 
QT syndromes, humans with ankyrin-B loss-of-function mutations may still 
display striking cardiac phenotypes including polymorphic ventricular tachycardia 
in response to emotional or physical stress, syncope, and sudden cardiac death 
(Zhang et al., 2004).  Therefore, the most significant common clinical features of 
‘ankyrin-B-syndrome’ are pleiotropy in the phenotype and a high rate of sudden 
cardiac death in the patient pedigrees.   
 
Dysfunction in ankyrin-G-based pathways 
 
 Rhythmic contraction of the heart requires rapid and coordinated waves of 
depolarization.  This depolarization is mediated by the activity of cardiac voltage-
gated Na (Nav channels) .  Nav1.5, encoded by SCN5A, is the major voltage-
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gated Nav channel expressed in vertebrate heart (Bezzina et al., 2001; Brugada 
and Brugada, 1992; Wang et al., 1995; Wedekind et al., 2001).  Human 
mutations in Nav1.5 may result in a variety of fatal inherited cardiac arrhythmias 
including Brugada syndrome, type 3 long QT syndrome, progressive cardiac 
conduction disorder (Lenègre disease) and sudden infant death syndrome 
(Bezzina et al., 2001; Brugada and Brugada, 1992).  Ability of Nav1.5 to 
coordinate cardiomyocyte depolarization is determined by its biophysical 
properties as well as its proper localization at excitable membrane domains in 
heart.  Nav1.5 biophysical properties have been a major area for molecular 
cardiology research for the past decade.  In contrast, the identity of the molecular 
mechanisms and cellular pathways underlying Nav1.5 targeting in heart have 
remained an important, but unresolved question. 
 Recent findings suggest that a second ankyrin-based pathway (ankyrin-G) 
is required for normal cardiac function (ankyrin-B and ankyrin-G are encoded by 
distinct genes).  Specifically, ankyrin-G-dependent function may be required for 
Nav1.5 targeting to excitable membranes in heart (Davis et al., 1996; Kordeli et 
al., 1995).  A potential role for ankyrin-G in Nav1.5 targeting in heart was first 
hypothesized based on the importance of ankyrin-G-based pathways for Nav 
channel targeting in brain.  Neuronal Nav channel isoforms including Nav1.2 and 
Nav1.6 directly associate with ankyrin-G from brain (Flucher and Daniels, 1989; 
Kordeli et al., 1998; Wood and Slater, 1998).  Additionally, ankyrin-G and 
neuronal voltage-gated Nav channels are co-expressed at multiple excitable 
membrane domains including nodes of Ranvier, axon initial segments, and the 
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neuromuscular junction .  Mice which have targeted ankyrin-G gene knock-out  in 
the cerebellum (described in ; ankyrin-G homozygous null in cerebellum, other 
tissues maintain normal ankyrin-G expression) are viable, but display abnormal 
clustering of neuronal Nav channel isoforms at nodes of Ranvier in peripheral 
nerve and axon initial segments (Jenkins and Bennett, 2001; Zhou et al., 1998).  
Loss of normal Nav channel localization leads to abnormal neuronal action 
potentials in these mice and pronounced ataxia (Jenkins and Bennett, 2001; 
Zhou et al., 1998).  These in vivo findings demonstrate that ankyrin-G-based 
cellular pathways are essential for Nav channel targeting to excitable membranes 
of brain.   
 190 kDa ankyrin-G is highly expressed in ventricular cardiomyocytes, co-
expressed with Nav1.5 at excitable membrane domains including intercalated 
discs and transverse-tubules, and co-immunoprecipitates with Nav1.5 from 
detergent-soluble extracts from heart (Mohler et al., 2004c).  Direct interaction 
between Nav1.5 and ankyrin-G requires a nine amino acid motif in the Nav1.5 DII-
III cytoplasmic loop (Garrido et al., 2003; Lemaillet et al., 2003).  This interaction 
motif is nearly identical to the nine amino acid ankyrin-G-interaction motif recently 
identified by two independent groups (Garrido et al., 2003; Lemaillet et al., 2003; 
Mohler et al., 2004c).    
 The significance of the ankyrin-G/ Nav1.5 interaction for cardiac function 
was established by the recent identification of a new human SCN5A mutation.  
This patient, heterozygous for an Nav1.5 E1053K mutation displays Brugada 
syndrome, an autosomal dominant arrhythmogenic disease characterized by 
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right bundle branch block, ventricular arrhythmia, and risk of sudden cardiac 
death (Mohler et al., 2004c).  Interestingly, the E1053K Brugada mutation is 
localized within the Nav1.5 nine residue ankyrin-binding motif and eliminates 
ankyrin-binding activity in vitro (Mohler et al., 2004c).    
 Consistent with the loss-of-function Brugada syndrome phenotype, Nav1.5 
E1053K lacking ankyrin-G-binding activity is not expressed at intercalated disc or 
transverse-tubule membrane domains of primary ventricular cardiomyocytes 
(Mohler et al., 2004c).  Instead, Nav1.5 E1053K-positive puncta are expressed 
throughout the cardiomyocyte cytoplasm (Mohler et al., 2004c).  One explanation 
for the loss of Nav1.5 E1053K at the membrane surface of cardiomyocytes is that 
E1053K represents a structural mutation that affects Nav1.5 folding and stability.  
However, HEK293 cells efficiently target both Nav1.5 and Nav1.5 E1053K to the 
plasma membrane (Mohler et al., 2004c).  Additionally, functional experiments 
indicate that there is no significant difference in Nav1.5 and Nav1.5 E1053K 
current density in HEK293 cells (Mohler et al., 2004c).  In addition to the 
abnormal targeting phenotype, Nav1.5 E1053K displays abnormal channel 
properties when analyzed in HEK293 cells  (Mohler et al., 2004c).  These results 
suggest a potential new function for ankyrin-G for ion channel gating.  This 
potential new role for ankyrin-G will be an obvious focus of future research.  The 
distinct trafficking phenotypes of Nav1.5 E1053K in cardiomyocytes versus 
HEK293 cells (epithelial-derived) suggest that Nav targeting mechanisms are 
cell-type specific.  Consistent with these data, previous findings demonstrate that 
cardiomyocytes display unique protein targeting/trafficking pathways not present 
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in epithelial-based cells for localization of membrane ion channels and 
transporters (Mohler et al., 2004c).  Together, these data demonstrate that 
cardiac ion channel and transporter targeting must be studied in the physiological 
context of the cardiomyocyte.    
 In summary, recent results identify the first in vivo evidence for a cellular 
pathway potentially required for Nav1.5 localization in heart.  Human mutations 
that interfere with this pathway lead to loss of normal Nav1.5 channel targeting, 
reduced INa, and risk of fatal cardiac arrhythmia (Brugada syndrome).  Although 
largely circumstantial, these data support a potential role for an ankyrin-G–
dependent pathway in Nav1.5 targeting to excitable membrane domains in the 
heart.  Therefore, we hypothesize that Nav1.5 is targeted to the cardiomyocyte 
membrane in an ankyrin-G-dependent manner.  
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CHAPTER V 
 
ANKYRIN-G IS REQUIRED FOR VOLTAGE-GATED SODIUM CHANNEL 1.5 
TARGETING 
 
 
Introduction 
 In this study, we report new data that conclusively links ankyrin-G activity 
and Nav1.5 membrane expression and localization in cardiomyocytes.  Using 
viral-mediated small hairpin RNA (shRNA) transfer into primary cardiomyocytes, 
we demonstrate that a full complement of ankyrin-G expression is required for 
Nav1.5 expression and membrane localization.  Specifically, reduced ankyrin-G 
expression decreases (1) total cellular Nav1.5 expression, (2) efficient membrane 
localization, and (3) total Na+ membrane current.  We also demonstrate that 
although ankyrin-G is required for normal Nav1.5 membrane expression, reduced 
ankyrin-G expression does not affect Nav1.5 channel kinetics.  Finally, we report 
the structural requirements for direct ankyrin-G–Nav1.5 interactions and show 
that direct intermolecular interaction between these two molecules is required for 
efficient channel membrane localization.  Together, these data identify the first 
clear cellular pathway for Nav channel trafficking in the heart. 
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Materials and Methods 
           In order to test our hypothesis we had to develop a primary cardiomyocyte 
system with reduced ankyrin-G expression.  We chose a lentiviral shRNA 
delivery system due to the difficulty in transducing cardiomyocyte cultures.  We 
used neonatal cardiomyocytes for the majority of the experiments due to the 
amenable use of lipid-mediated transfection strategies.  We also used adult 
cardiomyocytes to ensure the ankyrin-dependent pathway was important in adult 
cells.  To assure that ankyrin-G expression was reduced and to assess the affect 
of ankyrin-G reduction on cellular protein expression we used immunoblotting 
and immunofluorescent confocal microscopy.  Immunoelectron micrographs were 
generated to analyze the proximity and amount of Nav1.5 associated with 
ankyrin-G at the membrane.  We used electrophysiology to assess the functional 
effect of ankyrin-G reduction in cardiomyocyte cultures.  We defined the sites on 
the ankyrin-G membrane-binding domain required to interact with Nav1.5 by 
generating fusion proteins and performing binding studies. 
  
shRNA targets/cDNA constructs 
 Ankyrin-G–specific shRNA targets were selected based on their unique 
sequence presence of flanking 5' AA and 3' TT nucleotides (Brummelkamp et al., 
2002).  Human- and rat-specific targets were conferred by three unique 
nucleotides located at wobble positions.  The primer sequences include a nine 
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nucleotide linker flanked by sense and reverse complement of sense to facilitate 
hairpin formation and cleavage sites for Drosha (Figure 9).  Primers were created 
(Operon), annealed, and ligated into a modified pFIV-HI-Puro lentiviral vector 
(System Biosciences, Inc.).  The vector was modified to contain YFP driven by an 
independent H1PGK promoter to track transduced cells.  Feline 
immunodeficiency viruses were titered before transduction experiments based on 
visual transduction of YFP (>85%) in HEK293 cells. 
 Ankyrin-G constructs were generated using 190-kD ankyrin-G cDNA which 
was cloned into pEGFPN3 (CLONTECH; Palo Alto, CA) for GFP fusion 
expression.  GFP 190-kD ankyrin-G mutant constructs were made using Quik 
Change Mutagenesis (Stratagene).  Loop mutations were designed to replace 
ANK repeat beta-hairpin loop tip residues with two alanines.  Rescue constructs 
were made using GFP 190-kD ankyrin-G and ANK repeat mutants R14 and R15.  
All constructs were completely sequenced and confirmed to express protein in 
HEK293 cells. 
 
Immunoblots 
 After viral and/or rescue treatment, cells were collected into PBS, pH 7.4.  
Cells were lysed using radioimmunoprecipitation assay buffer (50 mM Tris, 150 
mM NaCl, 0.5% deoxycholic acid, 0.1% sodium dodecyl sulphate pH 8) 
containing protease inhibitor cocktail.  Detergent-soluble fractions were collected 
after high speed centrifugation, and protein concentrations were determined 
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using a bicinchoninic acid protein assay kit (Thermo Fisher Scientific).  Equal 
quantities of protein (20 µg) were analyzed by SDS-PAGE using NuPage 3-8% 
Tris-acetate gels (Invitrogen) and immunoblotting after transfer to nitrocellulose. 
Equal loading was assessed by transfer to Ponceau S and blotting with NHERF1.  
 
Neonatal rat cardiomyocytes 
 Hearts were dissected from postnatal day 1 rats and placed into Ham’s 
F10 with 1% penicillin/streptomycin.  Hearts were then aspirated of remaining 
blood, excised from atrial tissue and transferred to 1.5ml of Ham’s F10 with 1% 
penicillin/streptomycin with 0.05% trypsin EDTA.  The hearts were then minced 
using extra fine scissors and forceps into ~1.0mm pieces.  The diffusate was 
then triturated with a 1ml filtered tip ten times.  The trituration step was repeated 
after each of two fifteen minute intervals of incubation at 37°C.  Then 200μl each 
of collagenase (0.2mg/ml) and soybean trypsin inhibitor (2mg/ml) were added 
triturated and incubated for forty-five minutes at 37°C.  The cell slurry was then 
collected and spun down at 1600 rpm for five minutes.  The enzyme containing 
supernatant was removed and cells were resuspended in complete media (1:1 
DMEM: Ham’s F-10 with 1% penicillin/streptomycin and 20% fetal bovine serum. 
Cells were placed in 6-well tissue culture plates at one heart per well density and 
cultured for three hours at 37°C with 5% CO2 and 95% humidity (Bhasin et al., 
2007).  This step assists in the clearance of fibroblasts from the cell cultures and 
enriches the proportion of cardiomyocytes to fibroblasts.  After the pre-clearance 
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step cells are transferred to Fibronectin (50ng/ml) coated glass bottomed Mattek 
plates for imaging and 3.5 cm culture plates for biochemical analyses using 
complete medium.  After eighteen hours in culture the cells are washed with 
serum free 1:1 DMEM/F-10 media and the media is replaced with defined media 
(1:1DMEM:F-10, 0.10 µg/ml insulin, 0.50 µg/ml transferrin, 0.10 nM LiCl, 0.10 nM 
NaSeO4, and 0.01 nM thyroxine).  The cells are maintained with media changes 
every twenty-four hours.   
 
Adult cardiomyocytes 
 Myocytes were isolated from 250–300 g Sprague-Dawley rats (Grueter et 
al., 2006).  Rats were anesthetized with 50mg/g avertin (200μl/10g 
intraperitoneal).  Hearts were extracted and placed in Ca2+ free Tyrode’s solution 
at 10°C.  Fatty tissue and extraneous vasculature was removed and the aorta 
was affixed to perfusion cannula and perfused with calcium free Tyrode’s solution 
for six minutes at 38°C.  The Langendorff device was then switched to 
collagenase II/protease digestion buffer and perfused for sixteen minutes.  The 
ventricular myocardium was then removed from the cannula, minced, and cells 
were then dissociated by trituration and washed with culture media.  Acutely 
isolated cardiomyocytes were then plated at high density ( 2 x 106 per well), 
infected with rat-specific ankyrin-G shRNA virus or control virus for nine hours, 
and maintained for twenty-two hours at 37°C before experiments.  
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Binding experiments 
 GFP 190-kD ankyrin-G and mutants were expressed in HEK293 cells and 
purified using affinity-purified GFP Ig coupled to protein A agarose beads.  Cells 
were lysed in homogenization buffer (50 mM Tris HCl, 10 mM NaCl, 0.32 M 
sucrose, 5 mM Na EDTA, 2.5 mM Na EGTA, 1 mM PMSF, 1 mM 4-(2-
aminoethyl) benzenesulfonylfluoride hydrochloride (AEBSF), 10 µg/ml leupeptin, 
and 10 µg/ml pepstatin)  plus 1.0% Triton X-100 and 0.5% deoxycholate (Mohler 
et al., 2005a).  The extract was centrifuged at 100,000 g, and the supernatant 
was incubated with GFP Ig coupled to protein A–Sepharose.  Nav1.5 DII–DIII 
cytoplasmic loop was subcloned into pET15b for expression and purification as a 
hexahistidine fusion protein.  Purified proteins were incubated with GFP or control 
Ig coupled to protein A–Sepharose.  Protein bound to each mutant GFP 190-kD 
ankyrin-G was eluted, analyzed by immunoblotting, normalized for relative GFP 
ankyrin-G expression, and compared with wild-type GFP 190-kD ankyrin-G 
binding.  
 
Statistics 
 When appropriate, data were analyzed using a two-tailed t test, and P < 
0.05 was considered significant.  Values are expressed as the mean ± SD.  
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Virus generation 
 Ankyrin-G shRNAs were engineered into the pFIV lentiviral vector and 
packaged into viral pseudoparticles (System Biosciences, Inc.).  Constructs were 
cotransfected with packaging plasmids (pFIV-34N and pVSV-G) into HEK293TN 
cells using Effectene.  The HEK293FT cells were seeded the day before 
transfection at a density that would allow 40% confluence the day of transfection.  
Lipid complexes were incubated on the cells overnight and replaced with DMEM 
with 1% penicillin/streptomycin and 4% fetal bovine serum.  The viral 
pseudoparticle-containing supernatant was harvested after two days in culture 
and concentrated using Centriplus YM-30 columns.  The concentrate was stored 
at –80°C until used.   Fresh HEK293 cells were subsequently infected with the 
viral pseudoparticles for nine hours and assayed for transduction, eighteen to 
thirty hours post-infection using confocal imaging with the argon laser set to a 
514 nm excitation wavelength. 
 
Immunostaining/confocal microscopy 
 Cardiomyocytes were isolated, cultured, and processed for 
immunofluorescence as described previously (Cunha et al., 2007; Mohler et al., 
2003).  Secondary antibodies included anti–rabbit and anti–mouse Igs conjugated 
to AlexaFluor488 or 568 (Invitrogen).  Phalloidin-conjugated AlexaFluor633 was 
used for double-labeling experiments in Fig. 13.  After secondary antibody 
 70
treatment, cells were extensively washed, covered with Vectashield imaging 
medium (Vector Laboratories), and coverslips (#1) were applied.  Images were 
collected on a confocal microscope (510 Meta; Carl Zeiss, Inc.) with a 63x oil 1.40 
NA or 40x oil 1.30 NA lens (pinhole equals 1.0 airy disc; Carl Zeiss, Inc.) using 
imaging software (release version 4.0 SP1; Carl Zeiss, Inc.).  Images were 
collected using similar confocal protocols at room temperature.  In experiments in 
which both AlexaFluor488 and YFP were analyzed, the emission signal from 
AlexaFluor488 was collected from 500 to 515 nm, and the emission from YFP 
was collected from 530 to 565 nm.  Because YFP was only used to identify virus-
positive cells (versus identifying the localization of an YFP fusion protein), we 
used minimal laser power and detector gain (thus the minimal YFP image 
resolution) to collect YFP images to prevent potential signal bleed-through to the 
AlexaFluor488 image, in which protein immunolocalization was crucial. For 
images in Figs. 11, 12, and Fig.16, the YFP image was pseudocolored.  Images 
were imported into Photoshop CS (Adobe) for cropping and linear contrast 
adjustment.  
 
Plasma membrane sheet preparation/immunoelectron microscopy 
 Ventricular cardiac myocytes from adult Sprague-Dawley rats were 
obtained as described previously (Grueter et al., 2006).  Immunolabeling of the 
membrane sheets was performed by placing the grids on drops of primary 
antibody solution for 1 h on ice and rinsing six times for 5 min in PBS containing 
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BSA.  Grids were then incubated on drops of gold-conjugated secondary 
antibody solution (5 nm of goat anti–rabbit diluted 1:50 or 10 nm of goat anti–
mouse diluted 1:50 in PBS containing BSA; Electron Microscopy Sciences) for 1 
h on ice.  Grids were then rinsed three times for 5 min in PBS containing BSA 
followed by a 2-min fixation in 2.5% glutaraldehyde.  Finally, the grids were 
washed for 5 min in deionized water before being allowed to air dry.  Negative 
controls included grids labeled with secondary antibody alone.  Grids were 
visualized on a transmission electron microscope (H-70000; Hitachi). 
 
Antibodies 
 Antibodies used include anti-Nav1.5 (Alomone Laboratories), anti-NCX1 
(Swant), anti–connexin43 (Invitrogen), anti-Cav1.2 (Affinity BioReagents), anti-
NHERF1 (Sigma-Aldrich), affinity-purified Igs against ankyrin-B, ankyrin-G, and 
GFP (monoclonal and polyclonal), and goat anti–rabbit AlexaFluor568 
(Invitrogen). 
 
Electrophysiology experiments 
 Voltage-dependent Na+ and Ca+2 currents were measured using standard 
patch clamp techniques.  Whole-cell currents were recorded with an amplifier 
(Axopatch 200B; MDS Analytical Technologies), and the analogue signal was 
filtered using an eight-pole filter (Bessel) with a bandwidth of 5 kHz and was 
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digitized at a sampling rate of 50 kHz.  Borosilicate glass capillaries (VWR 
Scientific) were used to fabricate patch pipettes.  Electrode resistances ranged 
from 1 to 1.5 M , and seal resistances were 1–5 G .  Pipette seal resistances 
were compensated to >85% of the uncompensated value.  The whole-cell bath 
solution contained 10 mM NaCl, 130 mM choline chloride, 4.5 mM KCl, 1.8 mM 
CaCl2, 2.0 mM MgCl2, 10.0 mM Hepes, and 5.5 mM glucose, pH 7.35, titrated 
with KOH.  The pipette solution contained 130 mM CsCl, 0.5 mM CaCl2, 2 mM 
MgCl2, 5 mM Na2ATP, 0.5 mM GTP, 5 mM EGTA, and 10 mM Hepes, pH 7.3, 
titrated with CsOH.  All electrophysiology experiments were performed at room 
temperature (21–23°C).  
 Whole-cell voltage clamp Na+ current data were elicited from a holding 
potential of –120 mV to membrane potentials ranging from –110 to 30 mV in the 
presence of 2.0 mM CoCl2.  Voltage-dependent steady-state inactivation was 
determined using a paired two-pulse protocol.  Each conditioning voltage was 
paired with a control after 1.5 s.  A 500-ms conditioning pulse from –120 to 20 mV 
in 10-mV increments was followed by a test pulse to –30 mV.  The test pulse in 
each series was separated form the conditioning pulse by a 2-ms interval to –120 
mV.  The steady-state inactivation curves were constructed by normalizing 
currents to the maximal Na+ current elicited from a holding potential of –120 to –
30 mV for a duration of 20 ms.  The resulting curve was fitted using a Boltzmann 
distribution equation of the form INa = INa, max/ (1 + exp ([Vm – V1/2]/k)), where Vm is 
the conditioning pulse voltage, V1/2 is the voltage at half-inactivation, and k is the 
slope factor.  The whole-cell voltage clamp protocol showing INa and ICa in Fig. 5 
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F was elicited using the two-pulse paradigm shown in Fig. 5 G.  From a holding 
potential of –100 mV, INa was elicited by a 30-ms pulse to –30 mV.  The 
membrane potential was then hyperpolarized to –70 mV for 10 ms.  ICa was then 
elicited by a 50-ms pulse to 0 mV.  This protocol allowed the simple differentiation 
of INa from ICa as indicated by the unique ICa and INa current signatures in Fig. 5.  
All presented currents were normalized for cell capacitance.  Data were collected 
and analyzed using pCLAMP 9.0 software (MDS Analytical Technologies) and 
OriginPro 7.5 (OriginLab Corp.).  Analysis of variance was used to compare the 
nominal change in current density among the means.  Statistical significance is 
defined as P < 0.05.  
 
Results 
 
Generation of cardiomyocytes lacking ankyrin-G 
 We developed rat cardiomyocyte primary cultures with reduced ankyrin-G 
expression using lentiviral-mediated delivery of shRNA.  The shRNA was 
designed to target all identified ankyrin-G mRNAs and was specific for rodent 
ankyrin-G (versus human; Fig. 9, A and B).  We modified the lentiviral construct 
to encode YFP to enable the identification of transduced cells.  A human-specific 
ankyrin-G shRNA was generated for control experiments (Fig. 9 A). 
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Figure 9. 
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Figure 9.  Species-specific knockdown of 190-kD ankyrin-G in rat myocytes 
using lentiviral shRNA.  (A) Domain organization of 190-kD ankyrin-G with the 
site of shRNA target.  Rat, mouse, and human shRNA nucleotide target 
sequences.  Note that the human 190-kD ankyrin-G target sequence has three 
unique nucleotides in wobble base positions (asterisks) that render this target 
sequence resistant to the rat shRNA.  (B) The 21-nucleotide target sequence 
(sense) is separated by a short loop spacer sequence followed by 21 nucleotides 
that form the reverse complement of the target sequence.  (C) Rat and human 
species–specific shRNAs reduce 190-kD ankyrin-G expression.  Rat myocytes or 
human HEK293 cells were transduced with control virus, rat ankyrin-G shRNA, or 
human ankyrin-G shRNA.  Equal quantities of protein were analyzed by 
immunoblotting using affinity-purified ankyrin-G Ig or an antibody to an unrelated 
protein, NHERF1 (loading control).  Note that the rat-specific ankyrin-G shRNA 
effectively reduces the expression of 190-kD ankyrin-G in rat cardiomyocytes.  
Moreover, the expression of 190-kD ankyrin-G is reduced in HEK293 cells 
transduced with human-specific ankyrin-G shRNA. (D)  190-kD ankyrin-G protein 
levels from whole cell lysates of rat cardiomyocytes transduced with control virus, 
human-specific ankyrin-G shRNA virus (hAnkG shRNA), or rat-specific ankyrin-G 
shRNA virus (rAnkG shRNA) were analyzed by immunoblotting and quantitated.  
Numbers represent the mean ± SD (error bars) from four independent 
experiments. *, P < 0.05.  
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Rodent-specific ankyrin-G shRNA is efficient for reducing ankyrin-G expression 
and does not interfere with human ankyrin-G expression (Fig. 9).  Introduction of 
rodent-specific ankyrin-G shRNA into primary rat cardiomyocytes significantly 
reduced ankyrin-G protein expression (Fig. 9, C and D).  Likewise, human-
specific ankyrin-G shRNA reduced ankyrin-G expression in human-derived 
HEK293 cells (Fig. 9 C).  Finally, no significant decrease in ankyrin-G levels was 
observed in rat cardiomyocytes transduced with human-specific ankyrin-G 
shRNA (Fig. 9 D).  Equivalent viral expression was observed in each cell system 
(assessed by positive YFP fluorescence). 
 
Ankyrin-G is required for normal Nav1.5 expression and localization 
 
 Rat cardiomyocytes lacking a full complement of ankyrin-G expression 
were used to test the role of ankyrin-G for Nav1.5 expression.  As shown in Fig. 9, 
viral transduction of ankyrin-G shRNA significantly reduces ankyrin-G expression 
(transduction efficiency of 80–95% based on YFP fluorescence; Fig. 10). 
Moreover, a striking reduction in Nav1.5 protein levels was observed in the 
identical cell lysates from rat-specific ankyrin-G shRNA virally transduced 
myocytes (Fig. 10).  This reduction was specific to Nav1.5, as expression 
differences in cardiomyocyte membrane–associated proteins, including NHERF1, 
connexin43, ankyrin-B, Cav1.2 (Fig. 10), SERCA2, Na/K ATPase, or Na/Ca 
exchanger (not depicted), were not observed. 
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Figure 10. 
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Figure 10.  Nav1.5 expression is reduced in rat myocytes with reduced 
ankyrin-G expression.  Neonatal cardiomyocytes were transduced with rat- 
specific ankyrin-G shRNA virus.  After 22 h, myocytes were collected, and whole 
cell lysates were generated.  Equal protein concentrations were analyzed by 
immunoblot using affinity-purified ankyrin-G Ig and Nav1.5-specific antibody.  In 
parallel, blots were probed with an unrelated Ig to ensure equal protein loading 
(NHERF1).  Note that loss of 190-kD ankyrin-G expression in myocytes 
transduced with rat-specific ankyrin-G shRNA was paralleled by a significant 
reduction in Nav1.5 expression.  Reduced ankyrin-G expression did not affect the 
expression of ankyrin-B, connexin43, or Cav1.2.  Molecular masses are 
expressed in kilodaltons.  
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 The role of ankyrin-G on single cardiomyocyte Nav1.5 expression was 
examined using immunofluorescence and confocal microscopy.  In agreement 
with immunoblot data of cardiomyocyte populations (Fig. 10), reduced ankyrin-G 
expression resulted in a dramatic loss of Nav1.5 cellular expression (Fig. 11 C) 
compared with nontransduced (Fig. 11 A), YFP-transduced (Fig. 11 B), and 
human-specific ankyrin-G shRNA–transduced myocytes (Fig. 11 D). 
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Figure 11. 
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Figure 11.  Nav1.5 expression is reduced in single rat myocytes with 
reduced ankyrin-G expression.  (A–D) Control myocytes (uninfected; A) and 
cardiomyocytes transduced with control virus (YFP alone; B), rat-specific ankyrin- 
G shRNA virus (C), or human-specific ankyrin-G shRNA virus (D) were 
immunolabeled with ankyrin-G and Nav1.5-specific antibodies and imaged using 
identical confocal settings. Viral transduction was assessed by the presence of 
YFP fluorescence (pseudocolored in blue in B–D for clarity).  Note that only 
myocytes infected with rat-specific ankyrin-G shRNA virus displayed reduced 
ankyrin-G expression.  These myocytes consistently displayed a decreased 
expression of Nav1.5.  In fact, Nav1.5 expression in myocytes with reduced 
ankyrin-G expression (arrowheads in C) was limited to the perinuclear region 
(arrows in C).  Bars, 10 µm.  
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 Specifically, Nav1.5 expression appeared to only remain in the perinuclear 
region of cardiomyocytes lacking ankyrin-G expression (Fig. 11 C).  Loss of 
protein localization was limited to Nav1.5, as cardiomyocytes transduced with 
ankyrin-G shRNA displayed no difference in the expression or localization of 
either Cav1.2 or Na/Ca exchanger (Fig. 12). 
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Figure 12. 
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Figure 12.  Normal expression/distribution of Cav1.2 and NCX1 in 
cardiomyocytes lacking ankyrin-G.  Control myocytes (uninfected; A and C) 
and cardiomyocytes transduced with rat-specific ankyrin-G shRNA virus (B and 
D) were immunolabeled with ankyrin-G and Cav1.2 or Na/Ca exchanger 1 
(NCX1)–specific antibodies and imaged using identical confocal settings.  
Myocyte ultrastructure was visualized using phalloidin conjugated to 
AlexaFluor633 (dark blue images).  Viral transduction was assessed by the 
presence of YFP fluorescence (pseudocolored in turquoise in the right panels of 
B and D).  Bars, 10 µm. 
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Ankyrin-B is not required for Nav1.5 expression in cardiomyocytes 
 
 Ankyrin-B (encoded by ANK2) is required for the membrane targeting of 
Na/Ca exchanger, InsP3 receptor, and Na/K ATPase in cardiomyocytes (Mohler 
et al., 2005a).  Ankyrin-B and -G are structurally similar and share binding activity 
for protein partners, including beta-spectrin and Na/K ATPase (Devarajan et al., 
1994; Kizhatil and Bennett, 2004; Kizhatil et al., 2007b; Mohler et al., 2005a; 
Mohler et al., 2004e).  We used primary cardiomyocytes from ankyrin-B–null mice 
to test whether ankyrin-B expression is necessary for Nav1.5 membrane 
expression.  Confocal analyses of wild-type, ankyrin-B+/–, and ankyrin-B–null 
cardiomyocytes revealed no difference in Nav1.5 immunolocalization (Fig. 13, A–
C).  Therefore, even in myocytes completely devoid of ankyrin-B expression, 
Nav1.5 was normally expressed and properly localized.  These results 
demonstrate that ankyrin-G (not ankyrin-B) is the physiological binding partner for 
Nav1.5 in the heart. 
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Figure 13. 
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Figure 13.  Nav1.5 is normally expressed in cardiomyocytes with reduced 
ankyrin-B expression.  Immunolocalization of ankyrin-B and Nav1.5 in neonatal 
myocytes derived from wild-type (A), ankyrin-B+/– (B), and ankyrin-B–/– mice (C).  
Note that although ankyrin-B levels are reduced 50% in ankyrin-B+/– myocytes 
and nearly 100% in ankyrin-B–/– cardiomyocytes, there is no reduction in Nav1.5 
expression/localization.  Bars, 10 µm.  
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Ankyrin-G is required for normal Nav1.5-dependent Na+ current in 
cardiomyocytes 
 
 We made electrophysiological measurements to determine whether 
reduced ankyrin-G expression significantly affects Nav channel membrane 
current density in primary cardiomyocytes (Fig. 14).  Wild-type rat 
cardiomyocytes and cardiomyocytes transduced with human- or rat-specific 
ankyrin-G shRNA virus was analyzed for sodium current using whole-cell patch 
clamp (see Fig. 14 D [inset] for protocol). 
 Virally transduced cardiomyocytes were selected for electrophysiological 
measurements on the basis of positive YFP fluorescence.  Cardiomyocytes 
infected with human-specific ankyrin-G shRNA virus displayed no change in peak 
Na+ current compared with control (nontransduced) myocytes (note the current 
traces in Fig. 14 [A and B] and the current-voltage relationship in Fig. 14 D). 
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Figure 14. 
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Figure 14.  Reduced sodium current amplitude and current-voltage kinetics 
in myocytes with reduced ankyrin-G expression.  Nontransduced 
cardiomyocytes (control) and cardiomyocytes transduced with human- (hAnkG) 
or rat-specific (rAnkG) shRNA virus were analyzed for Nav1.5 current.  (A–C) 
Whole-cell patch clamp sodium current traces elicited control (A; 17 pF), human 
ankyrin-G–specific shRNA–transduced cells (B; 18 pF), and rat-specific ankyrin-
G shRNA–transduced cells (C; 16.8 pF). All cardiomyocytes displayed similar cell 
capacitance, and all traces are normalized for cell capacitance.  (D) Mean and 
normalized current-voltage relationship for neonatal rat ventricular 
cardiomyocytes.  Cardiomyocytes treated with control virus (black squares; n = 
10), human ankyrin-G shRNA virus (gray circles; n = 10), and rat ankyrin-G 
shRNA virus (white squares; n = 10).  (E) Normalized maximum sodium current 
amplitude in myocytes treated with control (black bar) and rat- (white bar) and 
human (gray bar)-specific ankyrin-G shRNA virus. *, P < 0.05. (F and G) 
Reduced ankyrin-G expression specifically affects cardiomyocyte sodium current.  
(F) Amplitude of Na+ and Ca2+ current in nontransduced (control) and rat 
neonatal cardiomyocytes transduced with ankyrin-G species-specific shRNA 
viruses.  Currents are elicited with the protocol shown in the inset (see Materials 
and methods for details).  Left panels depict Na+ and Ca2+ current in 
cardiomyocytes treated with control or human ankyrin-G–specific shRNA virus 
(hAnkG shRNA).  Right panels display the significant decrease in INa, but not ICa, 
cardiomyocytes transduced with rat-specific ankyrin-G shRNA virus (rAnkG 
shRNA).  All traces are normalized for cell capacitance.  (G) Reduced ankyrin-G 
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(Figure 14. continued) expression leads to reduced INa but does not affect 
cardiomyocyte ICa.  (E and G) Data are plotted as mean ± SEM (error bars; n = 
10).  Statistical difference was analyzed by analysis of variance.  
 
 In contrast, myocytes transduced with rat-specific ankyrin-G shRNA virus 
displayed striking decreases in peak Na+ current density (note the traces in Fig. 
14 C; currents normalized for cell capacitance).  In fact, several transduced cells 
that completely lacked detectable Na+ current (data not included in statistical 
analyses for Figs. 14 and 15; see Materials and methods) were observed.  
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Figure 15. 
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Figure 15.  Reduced ankyrin-G expression does not affect Nav1.5 
inactivation in primary cardiomyocytes.  Superimposed Nav1.5 inactivation 
curves obtained from neonatal rat cardiomyocytes treated with control (black 
squares) and species-specific (human, gray circles; rat, white squares) ankyrin-G 
shRNA viruses.  The normalized INa plotted against preconditioning pulse 
potential was fitted using a Boltzmann equation.  Voltage-dependent steady-state 
inactivation was determined using a paired two-pulse protocol.  Each 
conditioning voltage is paired with a control after 1.5 s.  A 500-ms conditioning 
pulse from –120 to 20 mV in 10-mV increments was followed by a test pulse to –
30 mV.  The test pulse in each series is separated from the conditioning pulse by 
a 2-ms interval to –120 mV.  Each point (INa) is normalized against the amplitude 
of corresponding control pulse (INamax).  Each point represents mean ± SEM 
(error bars; n = 5). 
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These functional data strongly support a role for ankyrin-G in Nav1.5 membrane 
surface targeting in cardiomyocytes.  To determine the specificity of the ankyrin-
G–based cellular pathway for ion channel membrane targeting in 
cardiomyocytes, we evaluated the effect of reduced ankyrin-G expression on a 
second critical cardiomyocyte membrane current.  Cav1.2-dependent calcium 
current (ICa) is required for normal cardiac excitability, and human Cav1.2 gene 
variants are associated with ventricular arrhythmia (Mohler et al., 2004d).  As 
expected, myocytes with reduced ankyrin-G expression displayed significant 
reduction in peak Na+ current amplitude (Fig. 14, F and G).  However, these 
identical myocytes displayed peak calcium current (ICa) measurements that were 
unchanged from those observed in control (nontransduced) or human-specific 
ankyrin-G shRNA virally transduced cardiomyocytes (see Materials and methods 
for protocol details; Fig. 14, F and G).  These data (combined with Nav1.5/Cav1.2 
immunoblot and immunostaining data in Figs. 10–12) establish that the cardiac 
ankyrin-G–targeting pathway is specific for Nav1.5 channels and that loss of 
Nav1.5 membrane expression in ankyrin-G–deficient cells is not simply the result 
of the general impairment of default myocyte membrane biogenesis/trafficking 
pathways. 
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Nav1.5 channel inactivation is unaffected in cardiomyocytes with reduced 
ankyrin-G expression 
 
 Human Nav1.5 Brugada Syndrome variant E1053K, which lacks ankyrin-
G–binding activity, is not efficiently targeted to the cardiomyocyte intercalated 
disc (Mohler et al., 2004c).  However, when introduced into heterologous 
HEK293 cells, this mutant channel is present at the plasma membrane but 
displays abnormalities in Nav1.5 inactivation (Mohler et al., 2004c).  Furthermore, 
similar data examining Nav1.2 biophysical properties in TsA201 cells support the 
concept that ankyrin-G could potentially regulate the biophysical properties of Nav 
channels in heterologous cells (Shirahata et al., 2006).  These studies did not 
determine whether the inactivation of wild-type Nav1.5 channels requires correct 
localization through ankyrin-G.  Therefore, we tested whether primary 
cardiomyocytes with reduced ankyrin-G expression displayed abnormalities in 
Nav channel inactivation.  No significant difference in Nav1.5 channel inactivation 
was observed in wild-type cardiomyocytes versus cardiomyocytes with reduced 
ankyrin-G expression (Fig. 14).  These data demonstrate that in the physiological 
context of a cardiomyocyte, normal Nav channel inactivation does not require 
ankyrin-G.  Surprisingly, inactivation of wild-type cardiomyocyte Nav1.5 is 
independent of physiological localization.  Thus, localization controls current 
density but not Nav1.5 inactivation.  These data strongly demonstrate the critical 
nature of studying ankyrin biology in the appropriate physiological context.  
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Direct interaction between ankyrin-G and Nav1.5 requires ANK repeat 14–15 
beta-hairpin loop tips 
 
 We identified the structural requirements on ankyrin-G for direct Nav1.5 
interaction using a series of ankyrin-G ANK repeat mutants (Fig. 16, A–C). 
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Figure 16. 
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Figure 16.  Direct interaction of ankyrin-G with Nav1.5 requires two ANK 
repeat beta-hairpin loop tips on the ankyrin-G membrane–binding domain.  
(A) 190-kD ankyrin-G includes a membrane-binding domain comprised of 24 
consecutive ANK repeats (green), a spectrin-binding domain (black), a death 
domain (blue), and a C-terminal domain (red).  (B) ANK repeat mutants were 
engineered in the context of full-length GFP 190-kD ankyrin-G and display 
alanine substitutions for the two residues located at the tip of each ANK repeat 
beta-hairpin loop (red arrowheads in B and purple sites in C).  (C) Crystal 
structure diagram of membrane-binding domain ANK repeats 13–24 (Michaely et 
al., 2002).  Exposed charged residues on beta-hairpin loop tips (sites of alanine 
mutagenesis) are colored in purple.  (D) Relative binding (compared with wild-
type GFP 190-kD ankyrin-G) of GFP 190-kD ankyrin-G ANK repeat mutants with 
purified Nav1.5 DII–DIII cytoplasmic domain (n = 3; *, P < 0.05).  Binding levels 
are corrected for the relative expression of each GFP–ankyrin-G mutant.  Error 
bars represent SEM.  (E) Nav1.5 binding sites (arrows) superimposed on the 
deduced crystal structure of the ankyrin-G membrane–binding domain (ANK 
repeats 13–24).  Ankyrin-G membrane–binding domain structure is based on the 
crystal structure of ANK repeats 13–24 of ankyrin-R (Michaely et al., 2002). 
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These mutants were created based on the identification of exposed, highly 
accessible residues on the beta-hairpin loop tips of the ankyrin-R membrane–
binding domain (repeats 13–24) crystal structure (Michaely et al., 2002) as well 
as the identification of membrane–protein binding sites at these sites in ankyrin-B 
(Cunha et al., 2007; Mohler et al., 2004b).  Specifically, each of the 24 
consecutive ANK repeats of an ankyrin membrane–binding domain fold as anti-
parallel pairs of alpha-helices connected by a beta-hairpin loop.  The large 
number of consecutive ANK repeats come together to form a super helix that 
surrounds a large central cavity (Michaely et al., 2002).  Thus, these variable 
beta-hairpin loops are highly accessible to the solvent for potential protein 
interactions (Fig. 17 C).  This strategy has been successfully used to map the 
binding sites on ankyrin-B for Na/Ca exchanger and InsP3 receptor (Cunha et al., 
2007; Mohler et al., 2004a). 
 24 individual ankyrin-G ANK repeat mutants were generated for binding 
analyses.  Each ankyrin-G mutant harbored two alanine substitutions in the 
variable beta-hairpin loop tips connecting each pair of ANK repeats within the 
membrane-binding domain (ANK repeats 1–24; Fig. 16, B and C).  Mutagenesis 
was performed in the context of GFP-tagged ankyrin-G (Mohler et al., 2004b).  
Mutant plasmids were completely sequenced to verify that no additional 
mutations were introduced during PCR amplification.  Wild-type ankyrin-G and 
each GFP ankyrin-G mutant were expressed in HEK293 cells.  Expressed 
proteins were immunopurified from the detergent-soluble fraction of the cells 
using immobilized affinity-purified GFP Ig and were incubated with purified His-
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tagged Nav1.5 DII–DIII cytoplasmic loop (site for ankyrin-G association on Nav1.5; 
(Mohler et al., 2004c).  The quantity of pure Nav1.5 DII–DIII bound to each mutant 
was determined by immunoblotting using a His tag Ig.  Using similar methods, the 
relative level of GFP–ankyrin-G mutant expression for each data point was 
determined.  The amount of Nav1.5 His-tagged DII–DIII bound to each ankyrin-G 
mutant was corrected for relative GFP–ankyrin-G expression in each 
experimental sample.  
 Although the majority of ankyrin-G mutants associated with Nav1.5 His-
tagged DII–DIII at levels similar to wild-type GFP–ankyrin-G, there was a 
significant reduction in DII–DIII binding to ankyrin-G mutants R13, R14, and R15 
(Fig. 16, D and E).  In fact, GFP–ankyrin-G mutants R14 and R15 displayed a 
near complete loss of Nav1.5 DII–DIII binding activity in these assays.  Together, 
our findings demonstrate that ankyrin-G–Nav1.5 binding is exclusively dependent 
on three critical elements (two beta-hairpin loops on ankyrin-G and a nine–amino 
acid motif on Nav1.5; (Mohler et al., 2004c).  
 
Human ankyrin-G expression rescues abnormal Nav1.5 localization 
 We performed rescue assays to determine whether the loss of Nav1.5 
localization in cardiomyocytes with reduced ankyrin-G expression was specifically 
caused by the monogenic loss of ankyrin-G.  Rat neonatal cardiomyocytes with 
reduced levels of ankyrin-G and Nav1.5 (as a result of the presence of rat-specific 
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ankyrin-G shRNA virus) were transfected with cDNA encoding human GFP–
ankyrin-G.  This GFP–ankyrin-G cDNA is resistant to the rat ankyrin-G shRNA 
(Fig. 10).  As expected, shRNA-transduced cardiomyocytes displayed decreased 
expression and abnormal localization of Nav1.5 (Fig. 17 B).  In contrast, shRNA-
transduced cardiomyocytes expressing human GFP–ankyrin-G cDNA displayed a 
Nav1.5 distribution similar to wild-type cardiomyocytes (Fig. 17 C).  These data 
demonstrate that abnormal Nav1.5 localization in ankyrin-G–null cardiomyocytes 
can be rescued by the exogenous expression of human ankyrin-G and reinforce 
the critical role for ankyrin-G in the subcellular localization of Nav1.5 in 
cardiomyocytes.  
 
Direct ankyrin-G–Nav1.5 interaction is required for Nav1.5 localization 
 We used the aforementioned ankyrin-G rescue assay with ankyrin-G 
mutants that lack Nav1.5-binding activity (Fig. 16) to determine whether direct 
ankyrin-G–Nav1.5 interactions are required for Nav1.5 localization in 
cardiomyocytes.  Ankyrin-G mutants lacking Nav1.5-binding activity were 
introduced into full-length human GFP–ankyrin-G cDNA to create human GFP–
ankyrin-G R14 and R15 (both resistant to rat ankyrin-G shRNA).  Cardiomyocytes 
with reduced ankyrin-G expression (transduced with rat ankyrin-G YFP virus) 
were transfected with human GFP–ankyrin-G or human ankyrin-G R14 or R15 
mutant cDNAs.  YFP-positive cardiomyocytes (express shRNA) were fixed and 
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immunostained. GFP–ankyrin-G is properly targeted in neonatal cardiomyocytes 
and rescues the normal expression of Nav1.5 (Fig. 17 C). 
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Figure 17. Nav1.5 targeting requires direct interaction with 190-kD ankyrin-
G.  (A and B) Immunolocalization of ankyrin-G and Nav1.5 in control 
(nontransduced) and rat ankyrin-G shRNA virally transduced neonatal 
cardiomyocytes.  Note the localization of Nav1.5 in the perinuclear region of 
shRNA-transduced myocytes (white arrows).  Yellow arrows denote remaining 
ankyrin-G staining in transduced myocytes, and asterisks mark sites of complete 
knockdown.  Virally transduced myocytes in the figure are denoted by positive 
YFP fluorescence (pseudocolored in blue).  (C) Cardiomyocytes expressing rat-
specific ankyrin-G shRNA (note the blue color denoting YFP expression) were 
transfected with GFP-labeled human ankyrin-G cDNA and immunolabeled with 
Nav1.5 and ankyrin-G antibodies.  Note that human GFP–ankyrin-G restores the 
localization of Nav1.5 to normal (compare Nav1.5 in B and C).  (D and E) GFP-
human ankyrin-G mutants (R14 and R15) that lack binding activity for Nav1.5 
(see Fig. 17) are unable to rescue to normal the aberrant localization of Nav1.5 
(note perinuclear distribution; arrows) in myocytes stably transduced with rat 
ankyrin-G shRNA (note positive YFP fluorescence).  Bars, 10 µm.  
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 In contrast, although both GFP–ankyrin-G R14 and GFP–ankyrin-G R15 
(Fig.17 D-E) were properly localized in transfected cardiomyocytes, there was no 
detectable rescue of Nav1.5 localization as observed with wild-type human GFP–
ankyrin-G (Fig. 17 C).  In fact, the localization of Nav1.5 in myocytes transfected 
with GFP–ankyrin-G R14–15 was similar to non-transfected myocytes lacking 
endogenous ankyrin-G expression (Fig. 17, B, D, and E).  Therefore, direct 
association of ankyrin-G with Nav1.5 is required for the membrane expression of 
Nav1.5 in ventricular cardiomyocytes.  
 
Ankyrin-G is required for Nav1.5 expression in adult cardiomyocytes 
 
 To test whether our findings in neonatal myocytes can also be applied to 
adult cardiomyocytes; we performed ankyrin-G shRNA viral transduction of 
freshly isolated adult rat cardiomyocytes.  Nav1.5 expression is most pronounced 
at the intercalated disc of adult cardiomyocytes (see Nav1.5 localization in the 
control myocyte; Fig. 18). 
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Figure 18. 
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Figure 18. Ankyrin-G is required for normal Nav1.5 expression in adult 
cardiomyocytes.  Control (untreated) adult rat cardiomyocytes (A) and adult rat 
cardiomyocytes virally transduced with rat-specific ankyrin-G shRNA (B) were 
immunolabeled for ankyrin-G (green) and Nav1.5 (red).  Pseudocolor image on 
the right depicts positive YFP fluorescence.  Yellow arrows indicate intercalated 
disc membrane domains (A and B).  The nucleus is denoted by N.  Note the 
predominant localization of Nav1.5 at the intercalated discs in control cells (we 
also observed T-tubule staining in most cells).  White arrows indicate the 
increased perinuclear localization/accumulation of Nav1.5 in myocytes with 
reduced ankyrin-G expression (B).  We observed normal localization of Nav1.5 in 
adult cardiomyocytes treated with control (YFP alone) virus. Bar, 10 µm. 
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 Therefore, we tested whether ankyrin-G expression is required for Nav1.5 
localization at the mature cardiomyocyte intercalated disc.  Reduced ankyrin-G 
expression in adult myocytes results in the reduced membrane expression of 
Nav1.5 (note the loss of Nav1.5 intercalated disc staining in Fig. 18 B), which is 
consistent with results in neonatal cardiomyocytes.  In fact, identical with our 
findings in neonatal cells, we observed that Nav1.5 localized to the perinuclear 
region (Fig. 18 B) in adult cardiomyocytes with reduced ankyrin-G expression.  
These data from isolated adult cardiomyocytes further confirm the role of the 
ankyrin-G–based protein-targeting pathway for Nav1.5 membrane expression in 
the heart. 
 
Discussion 
 
 In this study, we present the first report of a cellular pathway required for 
Nav channel trafficking in cardiomyocytes.  We demonstrate that direct interaction 
of the ankyrin-G membrane–binding domain and Nav1.5 DII–DIII loop is 
necessary for Nav1.5 expression and localization at the cardiomyocyte 
membrane surface.  Our new data provide compelling evidence that ankyrin-G–
dependent targeting of Nav1.5 is a fundamental requirement for cardiomyocytes 
and likely other excitable cells.  Ankyrin polypeptides have likely coordinately 
evolved to regulate electrical activity in the heart by targeting key ion 
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channels/transporters involved in controlling the cardiac action potential.  
Ankyrin-G directly associates with and targets Nav1.5 to the membrane surface 
(Fig. 19 A) to regulate inward Na+ current and, thus, action potential initiation and 
cardiomyocyte depolarization.  
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Figure 19. 
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Figure 19. Ankyrin-G and ankyrin-B ion channel/transporter complexes in 
the heart.  (A) Ankyrin-G is required for the targeting of Nav1.5 to the 
cardiomyocyte intercalated disc.  Although other Nav1.5-interacting proteins have 
been identified, it is not yet clear whether these are present in the ankyrin-G–
dependent protein complex.  (B) Ankyrin-B is required for the targeting of Na/Ca 
exchanger and Na/K ATPase to transverse-tubule membranes in the heart.  
InsP3 receptor targeting to the sarcoplasmic reticulum membrane requires direct 
interaction with ankyrin-B.  Cardiac ankyrin-B protein partners also include PP2A 
and beta2-spectrin.  
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Therefore, it is not surprising that human SCN5A variants that disrupt ankyrin-G 
interactions are associated with the Brugada Syndrome (Brugada et al., 1998), a 
cardiac syndrome associated with reduced inward INa (for review see (Napolitano 
and Priori, 2006)).  Clinical features of the Brugada Syndrome include fast 
polymorphic ventricular tachycardia typically occurring at rest or during sleep 
(Wilde and Priori, 2000).  In contrast, ankyrin-B targets distinct ion channels and 
transporters with central roles in cytosolic calcium extrusion during cardiac 
repolarization (Cunha and Mohler, 2006; Mohler et al., 2005a; Mohler et al., 
2004a; Mohler et al., 2002b; Mohler et al., 2003).   Ankyrin-B (product of the 
ANK2 gene) is required for targeting Na+/Ca2+ exchanger, Na/K ATPase, and 
InsP3 receptor to the transverse-tubule and sarcoplasmic reticulum in 
cardiomyocytes (Fig. 19 B; (Mohler et al., 2005a).  In contrast to Nav1.5-
associated Brugada Syndrome, ventricular tachycardia and syncopal events in 
the ankyrin-B syndrome are most often associated with adrenergic stimulation 
(e.g., emotional stress and/or exercise, similar to catecholaminergic polymorphic 
arrhythmia; (Mohler et al., 2005a; Mohler et al., 2007; Mohler et al., 2005b; 
Mohler et al., 2004d; Mohler and Wehrens, 2007).  
 In addition to targeting ion channels in cardiomyocytes, ankyrin-B was 
recently shown to be required for targeting of the regulatory subunit of the PP2A 
complex in primary cardiomyocytes (Fig. 19 B; (Bhasin et al., 2007).  This broad 
targeting role of ankyrin-B for both integral membrane and signaling proteins in 
the heart suggests that the ankyrin-G–targeting pathway may similarly facilitate 
the localization of additional myocyte proteins.  Moreover, our new findings for 
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ankyrin-G in Nav1.5 targeting identify an attractive, unconventional candidate 
disease gene for cardiac (arrhythmia and myopathy) and other excitable cell 
diseases.  
Based on the role of ankyrin-R in the erythrocyte (Bennett and Stenbuck, 1979b), 
cardiac ankyrin-G may simply act as a membrane scaffold to link integral 
membrane proteins (such as Nav1.5) with the underlying actin- and spectrin-
based cytoskeleton. In support of this role, we observe a significant level of 
Nav1.5 clustering on the plasma membrane surface with ankyrin-G as assessed 
by immunoelectron microscopy of cardiomyocyte membrane sheets (Fig. 20).  
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Figure 20. 
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Figure 20. Nav1.5 is clustered at the cardiomyocyte membrane surface with 
ankyrin-G. Immunogold electron microscopy of adult rat ventricular 
cardiomyocyte plasma membrane sheets. Anti–ankyrin-G Ig particles (10 nm 
gold) and anti-Nav1.5 Ig particles (5 nm gold; arrows) are found in clusters at the 
plasma membrane. The majority of Nav1.5-positive gold particles were clustered 
in proximity (<10 nm) to ankyrin-G–positive gold particles (see A, B, and D–F). 
However, we also observed a small fraction of Nav1.5-positive particles that were 
physically isolated from ankyrin-G (C). Membrane sheets labeled with gold-
conjugated secondary antibodies (negative control) were clear of any gold 
particles (not depicted). Bar, 50 nm. 
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  Alternatively, ankyrin-G may play an active role in the cellular trafficking of 
Nav1.5 to specific membrane domains. In theory, ankyrin-G could have multiple 
roles in both trafficking and stabilization/retention of Nav1.5 channels in the heart.  
Although these findings are beyond the scope of this study, elucidating the 
specific cellular roles of ankyrin polypeptides in excitable cells is an obvious 
future goal in the field.  An interesting finding in these studies was the peri-nuclear 
accumulation of Nav1.5 in myocytes lacking ankyrin-G (Figures 11 and 17). In fact, 
we consistently observed this peri-nuclear Nav1.5, albeit at a reduced level even in 
untreated wild-type myocytes.  Therefore, based on our data, we hypothesized that 
this compartment represented the site of ankyrin-G function for the trafficking of 
Nav1.5 to the cardiomyocyte plasma membrane.  To address this hypothesis, we 
prepared primary neonatal myocytes and evaluated the localization of Nav1.5 in by 
co-labeling with a variety of membrane and subcellular organelle markers (e.g. ER, 
Golgi, Trans-Golgi, endosome).  As shown in the upper panels of Figure 21, 
Nav1.5 is clearly organized at both plasma membrane and underlying peri-
nuclear sites. In regard to the subcellular distribution of Nav1.5, we observed 
significant co-localization with markers of the early endosome compartment 
(Figure 21. B).  In contrast, while there was apparent co-distribution of Nav1.5 
with TGN and other Golgi markers at low magnification, stringent high 
magnification analyses of the cells revealed juxtaposed Nav1.5 positive staining 
with these markers (Figure 21. A and C).  Therefore, these preliminary results 
suggest that Nav1.5 accumulates in a peri-nuclear endosomal compartment 
preceding it’s trafficking to the plasma membrane.  Moreover, our findings 
suggest that Nav1.5 accumulates in this compartment in the absence of ankyrin-
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G. Future experiments will be necessary to further characterize this trafficking 
pathway for Nav1.5 in the context of the primary myocyte.     
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Figure 21. 
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Figure 21. Localization of Nav1.5 at the plasma membrane and perinuclear 
subcellular membrane compartment in untreated neonatal cardiomyocytes. (A) 
Immunolocalization of Nav1.5, F-actin (phalloidin), and the cis-Golgi marker golgin 97 
at the plasma membrane focal plane (upper panels), lower panels show localization 
of Nav1.5 and golgin 97 in/near the peri-nuclear Golgi compartment.  (B) 
Immunolocalization of Nav1.5 and the early endosome marker EEA1 at the plasma 
membrane focal plane (upper panels), lower panels show localization of Nav1.5 and 
EEA1 in the early endosomal peri-nuclear compartment. Notice the significant 
amount of signal overlap of Nav1.5 and EEA1 in merged images.  (C) 
Immunolocalization of Nav1.5, F-actin (phalloidin), and the trans-Golgi marker 
GM130 (upper panels), lower panels show localization of Nav1.5 and GM130 in/near 
the trans-Golgi compartment.   
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Our electrophysiological measurements illustrate the importance of studying 
ankyrin–membrane protein interactions in the physiological context of a native 
cell.  Our previous work suggested that Nav1.5 E1053K lacking ankyrin-G–
binding activity displayed minor yet significant abnormalities in activation and 
inactivation when expressed in HEK293 cells (Mohler et al., 2004c).  However, 
when expressed in native cardiomyocytes, these biophysical abnormalities were 
inconsequential, as the majority of the channel lacked sufficient targeting 
information to even reach the plasma membrane (Mohler et al., 2004c).  Our new 
findings demonstrate that in myocytes lacking ankyrin-G, the small number of 
residual Nav1.5 channels that reach the plasma membrane have effectively 
normal biophysical characteristics.  These findings are in contrast to a recent 
publication that demonstrated abnormal inactivation gating of Nav1.2 in TsA201 
cells (modified HEK293 cell) lacking ankyrin-G (Shirahata et al., 2006).  Our new 
data suggest that these measurements should be re-evaluated in the context of a 
neuron.  
 Cardiomyocytes have clearly evolved unique channel trafficking pathways 
for the precise localization of specific ion channels to unique cardiomyocyte 
membrane domains. For example, although Nav1.5, Kv4.2, and connexin 43 are 
concentrated at the intercalated disc (Barry et al., 1995; Kanter et al., 1992; Maier 
et al., 2004; Mohler et al., 2004c) Kir2.1, Kir2.3, and Cav1.2 are primarily 
localized to transverse-tubule membranes (Carl et al., 1995; Melnyk et al., 2002; 
Sun et al., 1995). Moreover, significant populations of KvLQT1, ERG, minK, 
MiRP, Na/Ca exchanger, and Na/K ATPase are found at transverse-tubule and 
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peripheral sarcolemma membranes (Frank et al., 1992; Kieval et al., 1992; 
McDonough et al., 1996; Pond et al., 2000; Rasmussen et al., 2004; Wu et al., 
2006). Finally, high resolution imaging techniques have revealed unique 
transverse-tubule membrane domains that further segregate cardiac ion channel 
signaling complexes (Scriven et al., 2000).  Clearly, the molecular and structural 
characteristics of cardiac membrane domains represent a central feature for the 
regulation of local ion channel pathways and represent a relatively unexplored 
field in cell biology.  
 Ankyrin-based ion channel trafficking pathways have unique roles in 
specific cells. Recently, Pan and colleagues demonstrated the requirement of 
ankyrin-G association for the targeting of KCNQ2 and KCNQ3 (encode axonal M 
currents responsible for stabilizing neuronal resting potential) to axon initial 
segments. Specifically, ankyrin-G cerebellar-specific null mice display loss of 
KCNQ2/3 clustering at axonal initial segments (Pan et al., 2006). Moreover, the 
ankyrin-G–binding motif originally described in Nav1.2 and Nav1.5 (Garrido et al., 
2003; Lemaillet et al., 2003; Mohler et al., 2004c) is present in the C-terminal 
domain of KCNQ2/3 and is required for neuronal KCNQ2/3 targeting (Chung et 
al., 2006; Pan et al., 2006; Rasmussen et al., 2007). Interestingly, although 
nearly structurally identical, KCNQ1 (cardiac KvLQT1) lacks the C-terminal 
ankyrin-G–binding motif (Pan et al., 2006; Rasmussen et al., 2007). Consistent 
with this data, ankyrin-G and KCNQ1 are differentially targeted in ventricular 
cardiomyocytes (Mohler et al., 2004c; Rasmussen et al., 2004). Therefore, these 
data strongly suggest that ankyrin-based pathways operate in a cell type–specific 
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manner.  Furthermore the molecular mechanisms that target ankyrins are 
undefined and warrant further investigation. 
 In summary, our new findings show that ankyrin-G is the physiological 
binding partner for Nav1.5 in cardiomyocytes.  Loss of direct interaction between 
ankyrin-G and Nav1.5 results in abnormal Nav1.5 channel localization in primary 
cardiomyocytes.  Moreover, the loss of ankyrin-G expression affects Nav1.5 
expression, membrane localization, and, therefore, whole cell Nav1.5 activity.   
Based on recent ankyrin findings in the brain (Lencesova et al., 2004; Mohler and 
Bennett, 2005), heart (Kanter et al., 1992; Maier et al., 2004), and skeletal 
muscle (Kontrogianni-Konstantopoulos et al., 2004; Kontrogianni-
Konstantopoulos et al., 2006), our new findings likely represent only the first 
component of a larger ankyrin-G macromolecular signaling complex at 
cardiomyocyte excitable membrane domains. 
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CHAPTER VI 
 
FUTURE DIRECTIONS 
  
 Ankyrin-based trafficking pathways are vital for the normal expression of 
ion channels, transporters, cell adhesion molecules, and signaling proteins in 
several different cells (Cunha and Mohler, 2006; Kline and Mohler, 2006; Mohler 
et al., 2005b).  Our findings demonstrate that the proper localization and function 
of voltage-gated sodium channels in striated muscle is controlled by an ankyrin-
G-based cellular pathway (Lowe et al., 2008).  While these data have provided 
new insight into the molecular mechanisms governing Nav1.5 trafficking in 
excitable cells, a number of exciting questions remain unaddressed.  For 
example, while we have determined that ankyrin-G is required for Nav1.5 
targeting to the plasma membrane, the molecular basis of ankyrin-G trafficking is 
unknown.  Additionally, based on the role of ankyrins in other tissues for the 
biogenesis of membrane domains (e.g. epithelial membrane formation, initial 
segment development), does ankyrin-G play a similar role in the cardiomyocyte 
for membrane development? Moreover, once at the plasma membrane, what are 
the other components of the ankyrin-G-based intercalated disc complex?  Finally, 
how is ankyrin-G regulated in the cardiomyocyte, and what defines ankyrin-G 
specificity (versus other ankyrins) for protein interactions in vivo? 
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Targeting of ankyrins 
 
 An ankyrin-G-dependent pathway targets Nav1.5 (Lowe et al., 2008).  
However, to date, the pathways involved in the targeting of ankyrin-G are 
unknown.  Based on findings from a number of mammalian tissues, as well data 
from Drosophila and C. elegans, we hypothesize that ankyrin-G trafficking in 
cardiomyocytes will be dictated by a combination of both plasma membrane cell 
adhesion molecule and cytoskeletal element activity (Dubreuil, 2006; Dubreuil et 
al., 1997; Dubreuil et al., 2000; Hammarlund et al., 2000; Hammarlund et al., 
2007; Komada and Soriano, 2002).   
 A number of cell adhesion molecules have been demonstrated to target 
ankyrins.  Specifically, ankyrins associate with cell adhesion molecules including  
CD44 (Kalomiris and Bourguignon, 1988; Lokeshwar et al., 1994), E-cadherin 
(Kizhatil et al., 2007a), and L1-cell adhesion molecule family molecules (L1CAM, 
NrCAM, neurofascin, NgCAM, CHLI) (Ango et al., 2004; Davis et al., 1993; 
Dubreuil and Yu, 1994; Dzhashiashvili et al., 2007; Hortsch et al., 1998; Martin et 
al., 2008; Zhou et al., 1998).  Investigation of mouse node of Ranvier formation 
and development identified L1CAM members neurofascin-186 (NF-186) and 
neuron-glia related cell adhesion molecule (NrCAM) as the first molecules to 
establish protein clustering at nascent nodes (Lambert et al., 1997; Schafer, 
2006).  Specifically, NF-186 signals the recruitment of ankyrin-G in the central 
and peripheral nervous system (Schafer, 2006).  The ligand for NF-186 is termed 
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gliomedin, which can induce Nav channel clustering in cultures of neurons 
without Schwann cells (Eshed et al., 2005).   
 In addition to cell adhesion molecules, cytoskeletal elements including  
titin (Kontrogianni-Konstantopoulos and Bloch, 2003), tubulin (Davis and Bennett, 
1984), obscurin (Bagnato et al., 2003), and beta-spectrin (Bennett, 1979) have 
been implicated in the membrane localization of ankyrin polypeptides.   In 
erythrocytes, beta spectrin has a critical role for ankyrin-R membrane targeting 
(Bennett and Baines, 2001; Tse et al., 1990; Tse et al., 1991).  Mice lacking beta 
spectrin display loss of ankyrin-R at the plasma membrane resulting in 
spherocytosis (Bodine et al., 1984; Greenquist et al., 1978).  Human beta 
spectrin mutations affect ankyrin-R expression in the red blood cell and result in 
a similar human spherocytosis phenotype (Delaunay et al., 1996; Hassoun and 
Palek, 1996).   In the central nervous system, mice lacking beta-IV spectrin 
display loss of ankyrin-G at axon initial segments and nodes of Ranvier (Komada 
and Soriano, 2002).  Finally, in polarized epithelial cells, loss of beta-II spectrin 
affects ankyrin-G membrane localization resulting in abnormal lateral membrane 
formation (see below)(Kizhatil et al., 2007b).  In contrast to these findings for 
ankyrin-G, recent findings from our lab suggest that beta-II spectrin is not 
required for ankyrin-B targeting in cardiomyocytes (Mohler et al., 2004e).  
Together, these findings suggest that both membrane and cytoskeletal elements 
may prove critical for ankyrin-G targeting to the cardiomyocyte intercalated disc.  
Future experiments using our neonatal and adult myocyte systems will be 
valuable to characterize these pathways as well as intracellular trafficking 
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systems (Rabs, Bves, ARFs, myosins, etc) for ankyrin-G (Du et al., 2008; 
Grosshans et al., 2006; Myers and Casanova, 2008; Sartore et al., 1981; Smith 
et al., 2008).   
 
Ankyrins are critical for the establishment of membrane domains 
 
 In addition to roles in protein targeting, ankyrin-G may play an additional 
critical role in the development of the cardiomyocyte intercalated disc membrane 
domain.  Data from cerebellar-specific ankyrin-G knockout mice, siRNA-treated 
human bronchial epithelial cells, and siRNA-injected mouse embryos support the 
necessity of ankyrin-G in membrane development (Kizhatil et al., 2007a; Kizhatil 
et al., 2007b).  In the central nervous system, ankyrin-G is critical for the 
development of the AIS and node of Ranvier (Jenkins and Bennett, 2001; Zhang 
and Bennett, 1998).  Specifically, mice lacking ankyrin-G in the cerebellum 
display decreased thickness of the molecular layer (Jenkins and Bennett, 2001; 
Zhang and Bennett, 1998; Zhou et al., 1998).  Loss of molecular layer thickness 
and electrogenic properties in ankyrin-G null Purkinje neurons is thought to lead 
to cell degeneration that results in 60% fewer cells, when compared to littermate 
controls (Zhou et al., 1998).   
 In polarized epithelial cells, loss of ankyrin-G results in loss of lateral 
membrane, that subsequently increases cross-sectional area and reduces the 
height of the cells, changing the cells from columnar to squamous morphology 
(Kizhatil and Bennett, 2004).  Loss of ankyrin-G also disrupts de novo biogenesis 
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of epithelial cell membranes following cytokinesis, as evidenced by a dramatic 
increase in binucleate cells (Kizhatil and Bennett, 2004).  Bennett and colleagues 
have also suggested that the ankyrin-G pathway is critical for organizing the E-
cadherin complex at sites of cell-cell contact in epithelial cells (Kizhatil and 
Bennett, 2004).  Moreover, recent experiments show that ankyrin-G is required 
for exit of E-cadherin from the Trans-Golgi network, accumulation of E-cadherin 
at sites of cell-cell contact, and the process of compaction in mouse embryos 
(Kizhatil et al., 2007a).  Relevant to the cardiomyocyte, ankyrin-G was recently 
reported to bind to N-cadherin, a protein critical for the development and 
maintenance of the intercalated disc (Kizhatil et al., 2007a; Oxford et al., 2007; 
Zuppinger et al., 2000).  Interestingly, developmental abnormalities and/or 
disruption of intercalated disc structure have been linked to severe cardiac 
diseases, including dilated cardiomyopathies, cardiac-conduction disease, and 
cardiac hypertrophy (Awad et al., 2008; Li et al., 2008; Oxford et al., 2007; 
Perriard et al., 2003; Saffitz, 2005; van Tintelen et al., 2007). 
 Together, these data suggest that ankyrin-G could play a significant role in 
cardiac development at the level of compaction in the blastocyst, phospholipid 
accumulation in the membrane, and/or formation of specialized excitable cell 
membranes including the intercalated disc.  The development of a cardiac-
specific ankyrin-G null model mouse system will be critical to evaluate the role of 
ankyrin-G in cardiac development and mature myocyte membrane maintenance 
and function.   Finally, Nav1.5 itself appears to be important as a developmental 
checkpoint for the cardiomyocyte (Papadatos et al., 2002).  For example, fetal 
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Scn5a null mice display severe structural heart defects, abnormal cardiac 
contractility, and undergo autolysis by embryonic day 12 (Papadatos et al., 
2002).  Thus, ankyrin-G-dependent and downstream elements appear to play 
important roles in development and will be important topics for future research.  
 
Ankyrin-based signaling complex 
 
 Nav1.5 is a key component of the ankyrin-G-based intercalated disc 
protein complex (Lowe et al., 2008; Maier et al., 2004; Mohler et al., 2004c).  An 
obvious future direction is to identify other critical structural (see above) and 
signaling components of this ankyrin-G complex.  For example, the 
phosphorylation state of Nav1.5 is clearly important for the function of the channel 
(Abriel, 2007; Wagner et al., 2006).  We hypothesize that ankyrin-G may play a 
role in coordinating local Nav1.5 phospho-regulation.   There are several kinases 
thought to modulate the activity of Nav1.5 including protein kinase A (PKA) (Baba 
et al., 2004; Hallaq et al., 2006; Murray et al., 1997), Ca2+/calmodulin-dependent 
kinase II delta-c (CaMKIIdelta-c) (Wagner et al., 2006), protein kinase C (PKC) 
(Wagner et al., 2006), adenosine monophosphate-activated protein kinase 
(AMPK) (Arad et al., 2007; Light et al., 2003), and Src-family tyrosine kinases 
(including Fyn) (Ahern et al., 2005).   
 Nav1.5 has been identified as a target of PKA signaling in myocytes (Baba 
et al., 2004; Murray et al., 1997).  Specifically, beta-adrenergic activation drives 
the up regulation of cellular cyclic AMP and increases the activity of PKA.  This 
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increase in PKA has been linked with forward trafficking of Nav1.5 to the plasma 
membrane (Baba et al., 2004; Hallaq et al., 2006).  It will interesting in future 
studies to determine whether ankyrin-G plays a role in this specific trafficking 
pathway, or whether this pathway is more closely related to the proposed 
caveolae-based membrane trafficking system . 
In addition to PKA signaling, recent studies identified that CaMKII can 
directly bind and phosphorylate Nav1.5 (Wagner et al., 2006).  In cells that over-
express CaMKIIdelta-c, there was a Ca2+-dependent shift of inactivation to 
hyperpolarized potentials, the recovery from inactivation was slowed, and the 
cells displayed an increase in persistent INa (Abriel, 2007; Wagner et al., 2006).  
These biophysical modifications were rate-dependent and therefore could lead to 
a Brugada syndrome phenotype at rapid heart rates, or an LQT3 phenotype at 
slow heart rates (Abriel, 2007; Wagner et al., 2006).  Interestingly, CaMKIIdelta-c is 
up regulated in patients with heart failure and therefore may lead to rate-
dependent arrhythmias in diseased patients (Abriel, 2007; Wagner et al., 2006). 
PKC-dependent phosphorylation of Nav1.5 is hypothesized to reduce the 
ability of the channel to conduct current and shifts steady state inactivation to 
more hyperpolarized potentials (Murray et al., 1997; Wagner and Maier, 2006).  
Previous data suggested that PKC activity can lead to a down regulation of 
Nav1.5 at the membrane surface (Murray et al., 1997).  However, the role of 
PKC-dependent activity in normal physiological function and Nav1.5 surface 
expression remains to be clearly demonstrated.   
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The role of protein tyrosine kinases (various growth factors and Src family 
kinases) is very important in the regulation of ion channel biophysics (Ahern et 
al., 2005).  For example, Fyn (discussed in Chapter III) is a potential member of a 
local Nav1.5 signaling complex that causes a positive shift in the threshold of 
inactivation (Ahern et al., 2005).  The positive shift in inactivation due to co-
expression of constitutively active Fyn in HEK293 cells that stably express 
Nav1.5 can lead to persistent INa (Ahern et al., 2005).    Given the diverse set of 
kinases discussed above, another interesting family of proteins to consider as 
part of the local signaling complex of Nav1.5 are protein phosphatases. The 
phosphatases PTPH1 (Davis et al., 2001) and PP2A (Bhasin et al., 2007) were 
discussed in Chapters III and V. 
The potential modulatory activity of proteins known to organize multiple-
component signaling complexes (including ion channels and kinases) such as 
clathrin and caveolin-3 are also potentially relevant for the ankyrin-G complex 
(Abriel, 2007).  Clathrin is a well characterized component of several signaling 
complexes such as lipid rafts and a known binding partner of ankyrins (Maguy et 
al., 2006; Tombler et al., 2006).  The specific physiological contribution of 
caveolae remain a topic of investigation due to the broad spectrum of ion 
channels and signaling proteins thought to be active partners in the caveolar-
compartment of myocytes (Abriel, 2007; Baba et al., 2004; Cusdin et al., 2008; 
Palygin et al., 2008).   
Together, these data set the stage for future experiments to further 
evaluate local signaling pathways that control Nav1.5.  Based  on the linkage of 
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the number of signaling pathways with Nav1.5, it will be interesting in future 
experiments to determine the role of ankyrin-G in recruiting and organizing 
signaling pathways at local membrane domains in myocytes.  Moreover, it will be 
important to determine if other phospho-targets including ion channels, 
transporters, cytoskeletal elements, and/or signaling molecules are modulated by 
ankyrin-G in the myocyte.   
 
Regulation of ankyrin-based activity 
 
Ankyrin-based pathways play critical physiological roles in excitable and non-
excitable cells.  However, little is known regarding the regulation of the ankyrins 
themselves.  Moreover, little is known regarding the mechanisms that determine 
specificity between ankyrin isoforms.  Combinations of biochemical- and cell-
based analyses have gleaned what little we know about these transcriptional, 
translational, and post-translational pathways. 
  Targeted analysis of ANK1 gene regulation has revealed the promoter 
and transcription elements necessary for ankyrin-R expression (Gallagher et al., 
2000).  Promoter variants of ANK1 block binding of TATA-binding protein that 
results in disruption of TFIID complex assembly and aberrant transcription 
(Gallagher et al., 2005).  Further analyses into ankyrin-R expression revealed 
that alternative exon usage is used for the transcription of ankyrin-R in the brain 
(Gallagher et al., 1997).    Analysis of small ankyrin-1 (links myofibrils with the 
SR) revealed that expression is driven by a muscle-specific promoter, further 
 132
supporting tissue-specific expression of ankyrin isoforms (Birkenmeier et al., 
1998; Gallagher and Forget, 1998; Zhou et al., 1997).   
 Translational mechanisms further regulate ankyrin expression by 
demonstrating tissue-specific spliced forms of ANK1 (Gallagher et al., 1997).  
Subsequent analyses demonstrate that there are several splice forms of ANK1 
and that splicing of the regulatory domain results in altered function of the protein 
product (Gallagher et al., 1997; Lambert and Bennett, 1993; Lambert et al., 1990; 
Lux et al., 1990b).  Ankyrin-G is also alternatively spliced in a tissue-specific 
manner, and within the regulatory domain (Hopitzan et al., 2005).  Similar to 
ankyrin-R, ankyrin-G was discovered to maintain two alternative start sites for 
translation (Peters et al., 1995).  Finally, alternate length polyadenylation signals 
were discovered as another modulator of translation in ankyrin-R (Gallagher et 
al., 1997).   
 The first evidence for post-translational modification of ankyrin came from 
studies of the neuronal isoforms of ankyrin-G (Zhang and Bennett, 1996).  The 
neuronal isoforms that localize to the nodes of Ranvier are post-translationally-
modified by O-linked N-acetylglucosamine within a serine-rich insert in the 
regulatory domain (Zhang and Bennett, 1996).  There is also a high 
concentration of potential phospho-regulation sites between the spectrin-binding 
and membrane–binding domain (Peters et al., 1995).  Although there is 
incomplete evidence that these motifs are phosphorylated in vivo, the charged 
structures and salt sensitivity of ankyrin polypeptides, suggests that 
phosphorylation may dramatically affect the tertiary folding of the protein (Abdi et 
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al., 2006; Davis et al., 1989; Hall and Bennett, 1987; Michaely and Bennett, 
1993; Michaely and Bennett, 1995a; Peters et al., 1995).  Recent studies have 
identified the importance of inhibitor of kappa-B kinase (IKKalpha/beta)  activity and 
the localized accumulation of phosphorylated-inhibitor of kappa-B (pIKb) in 
establishment of the AIS (Sanchez-Ponce et al., 2008).  Inhibition of this pathway 
eliminated the accumulation of ankyrin-G and Nav1.5 at the AIS (Sanchez-Ponce 
et al., 2008). These data suggest the potential modulation of the ankyrin-G-
pathway by phospho-proteins that are downstream of several signaling 
pathways.  However, the specific molecular mechanism of pIKb modulation of 
ankyrin-G and whether this pathway is required for accumulation of ankyrin-G 
and Nav1.5 at the intercalated disc in cardiomyocytes has not been defined.   
 Structural and biochemical analysis of the membrane-binding domain has 
determined that protein folding is also critical for ankyrin function (Davis et al., 
1989; Michaely and Bennett, 1993; Michaely and Bennett, 1995a).  Specifically, 
the binding sites for anion exchanger on ankyrin-R membrane-binding domain 
are along a non-contiguous stretch of residues (Davis et al., 1989).  Further 
analysis of how the anion exchanger is bound by ankyrin-R revealed that the 
tertiary structure of the membrane-binding domain was as important as the 
primary residue sequence (Michaely and Bennett, 1993; Michaely and Bennett, 
1995b).  Although these studies provided important clues about what determines 
specificity of the membrane-binding domain for binding proteins, the high degree 
of residue conservation between ankyrin isoforms still require exploration to 
address the question of ankyrin isoform specificity.  For example, the localization 
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of the Na+/K+ ATPase is ankyrin-G-dependent in kidney, but surprisingly ankyrin-
B-dependent in cardiomyocytes, even though both isoforms readily associate 
with the pump in vitro and are expressed in the respective tissues (Gallagher et 
al., 1997; Mohler et al., 2002a; Thevananther et al., 1998).   
 The first clues for domain specificity and intermolecular interactions of 
ankyrin isoforms came from studies of ankyrin-R that demonstrated that an 
alternatively spliced fragment associated with the longer isoform (ankyrin-R 2.2) 
and modulated the availability of the isoform to bind spectrin and the anion 
exchanger (Gallagher et al., 1997; Lambert and Bennett, 1993; Lambert et al., 
1990; Lux et al., 1990a).  Subsequent studies for intermolecular interactions with 
ankyrins identified that obscurin (see above) and the heat-shock protein Hsp40 
can bind the carboxy-terminal domain of ankyrin-B (Kontrogianni-
Konstantopoulos et al., 2003; Mohler et al., 2004b).  Analyses done to determine 
the specificity of ankyrin-B versus ankyrin–G protein domains (Membrane-
binding, Spectrin-binding, Carboxy-terminal (MSC)) showed that the carboxy-
terminal domain of ankyrin-B has regulatory properties for protein-protein 
interactions and membrane targeting (localization of InsP3 and RyR)(Mohler et 
al., 2002a).  However, the specific regulatory properties of ankyrin-G in heart are 
the target of future experiments.  Recent mutagenesis experiments of the 
carboxy-terminal domain in ankyrin-B have identified a unique domain in ankyrin-
B that is critical for cardiac function (Abdi et al., 2006).  These experiments 
identified a large non-homologous region between ankyrin-B and ankyrin-G that 
has intramolecular regulatory activity (Abdi et al., 2006).  Specifically, a region 
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within the carboxy-terminal domain binds the membrane-binding domain and 
changes the conformation and availability of the molecule (Abdi et al., 2006).  
Moreover, biochemical and structural studies of ankyrin polypeptides show that 
the charged residues are likely to impart structural modification after changes in 
charge (phosphorylation) or hydrophobicity (Abdi et al., 2006; Davis and Bennett, 
1994; Davis et al., 1991; Hall and Bennett, 1987; Michaely and Bennett, 1993; 
Michaely and Bennett, 1995a, b; Mohler et al., 2004b).  These conformational 
changes may have functional significance in modulating signaling complex 
activity, associated ion channel gating and/or specialized membrane domain 
conformation.  Together, these data demonstrate several pathways to investigate 
the intricate regulation of ankyrin-G activity and expression.  Future experiments 
designed to evaluate the domain-specific regulation of ankyrin-G will be vitally 
important in understanding ankyrin-G-dependent pathways in cardiomyocytes.      
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